Tobira Therapeutics Inactive 10-K12 Feb 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Feb. 06, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	RGDO
Entity Registrant Name	REGADO BIOSCIENCES INC
Entity Central Index Key	1311596
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		33,609,212
Entity Public Float			$153.60

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$51,557	$30,688
Restricted cash	81	82
Prepaid expenses	827	2,147
Other assets	1,693	6,211
Total current assets	54,158	39,128
Property and equipment, net	239	108
Intangible assets, net		1,823
Other non-current assets		4,694
Total assets	54,397	45,753
Current liabilities:
Accounts payable	185	1,557
Accrued expenses	6,298	5,524
Warrant liability	8	19
Current portion of long-term debt	2,629	2,000
Total current liabilities	9,120	9,100
Long-term debt		2,452
Total liabilities	9,120	11,552
Commitments (Note 6)
Stockholders' equity:
Common stock, $0.001 par value; 500,000,000 shares authorized; 33,609,212 and 21,310,614 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively	34	21
Additional paid-in-capital	232,502	179,159
Accumulated Deficit	-212,091	-144,979
Total stockholders' equity	45,277	34,201
Total liabilities and stockholders' equity	54,397	45,753
Series F Convertible Preferred Stock [Member]
Stockholders' equity:
Convertible preferred stock	$24,832

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	33,609,212	21,310,614
Common stock, shares outstanding	33,609,212	21,310,614
Series F Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$1,000	$1,000
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	10,000	0
Convertible preferred stock, shares outstanding	10,000	0

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Total revenue:
Operating expenses:
Research and development	-54,926	-26,542
General and administrative	-11,699	-7,297
Total operating expenses	-66,625	-33,839
Loss from operations	-66,625	-33,839
Other (expense) income:
Interest income	88	80
Interest expense	-575	-680
Total other expense	-487	-600
Net loss	-67,112	-34,439
Deemed dividend related to beneficial conversion feature of Series F convertible preferred stock	-14,840
Net income (loss) available to common stockholders	-81,952	-34,439
Net loss attributable to stockholders
Net loss attributable to preferred stockholders	-3,972
Net loss attributable to common stockholders - basic and diluted	-77,980	-34,439
Comprehensive loss applicable to all stockholders	($81,952)	($34,439)
Loss per share - basic and diluted	($2.54)	($4.59)
Weighted-average common shares - basic and diluted	30,658,820	7,499,661

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders Equity (USD $)	Total	Common Stock [Member]	Additional Capital [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]	Series F Convertible Preferred Stock [Member]	Accumulated Deficit [Member]
In Thousands, except Share data	Total	Common Stock [Member]	Additional Capital [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]	Series F Convertible Preferred Stock [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2012	$16,314		$4,804	$5,778	$19,888	$22,978	$51,237	$22,169		($110,540)
Beginning balance, shares at Dec. 31, 2012		221,000		5,798,000	16,667,000	17,037,000	71,667,000	31,437,000
Issuance of preferred stock, value	10,163							10,163
Issuance of preferred stock, shares								14,320,000
Issuance of common stock, value	41,075	12	41,063
Issuance of common stock, shares		11,672,000
Conversion of preferred stock to common stock upon initial public offering, value		9	132,204	-5,778	-19,888	-22,978	-51,237	-32,332
Conversion of preferred stock to common stock upon initial public offering, shares		9,397,000		-5,798,000	-16,667,000	-17,037,000	-71,667,000	-45,757,000
Issuance of common stock upon exercise of warrants, value	2		2
Issuance of common stock upon exercise of warrants, shares		13,000
Issuance of common stock upon exercise of options, value	33		33
Issuance of common stock upon exercise of options, shares		8,000
Stock compensation	988		988
Other	65		65
Net loss	-34,439								1	-34,439
Ending balance at Dec. 31, 2013	34,201	21	179,159	0	0	0	0	0	1	-144,979
Ending balance, shares at Dec. 31, 2013		21,311,000
Issuance of common stock from private placement offering, value	18,601	4	18,597
Issuance of common stock from private placement offering, shares		4,000,000
Private placement offering, adjustment to net issuance costs	36		36
Issuance of common stock, value	57,554	11	57,543
Issuance of common stock, shares		10,279,000
Issuance of common stock upon exercise of warrants, value	1		1
Issuance of common stock upon exercise of warrants, shares		7,000
Issuance of common stock upon exercise of options, value	52		52
Issuance of common stock upon exercise of options, shares	12,161	12,000
Exchange of common stock, value	-16	-2	-24,838						24,824
Exchange of common stock, shares		-2,000,000							10,000
Recognition of beneficial conversion feature on Series F preferred stock	14,840		14,840
Accretion of beneficial conversion	-14,840		-14,840
Stock compensation	1,952		1,952
Net loss	-67,112									-67,112
Ending balance at Dec. 31, 2014	$45,277	$34	$232,502						$24,832
Ending balance, shares at Dec. 31, 2014		33,609,000							10,000	-212,091,000

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Stockholders Equity (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Issuance costs		$147
Common Stock [Member]
Issuance costs	4,200	5,611
Issuance costs and placement fees	1,400
Series E Convertible Preferred Stock [Member]
Issuance costs		$147

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013
Cash flows used in operating activities:
Net loss	($67,112,000)	($34,439,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	127,000	61,000
Amortization of patents and licenses	156,000	20,000
Impairment of intangible assets	2,057,000	371,000
Impairment of clinical trial supplies	8,190,000	0
Accrued final bank fee	87,000	55,000
Amortization of debt discount	91,000	61,000
Amortization of debt issuance costs	31,000	108,000
Change in fair value of warrant liability	-11,000	-60,000
Stock-based compensation	1,952,000	988,000
Loss on disposal of property and equipment	52,000	2,000
Other		65,000
Changes in operating assets and liabilities:
Prepaid expenses	1,320,000	-1,890,000
Other assets	-3,668,000	-1,708,000
Other non-current assets	4,658,000	-4,462,000
Accounts payable	-1,372,000	1,354,000
Accrued expenses	774,000	4,738,000
Net cash used in operating activities	-52,668,000	-34,736,000
Cash flows used in investing activities:
Change in restricted cash	1,000
Purchase of property and equipment	-310,000	-105,000
Patent and license acquisition costs	-390,000	-543,000
Proceeds received from sale of patents		100,000
Net cash used in investing activities	-699,000	-548,000
Cash flows from financing activities:
Proceeds from issuance of common stock from public offering, net of underwriting discounts and issuance costs	76,191,000	41,152,000
Proceeds from sale of preferred stock, net of issuance costs		10,163,000
Proceeds from borrowings on bank loan		4,500,000
Repayment of borrowings on bank loan	-2,000,000	-4,500,000
Payment of bank origination fee		-85,000
Payment of debt issuance costs		-57,000
Proceeds from issuance of common stock upon exercise of options and warrants	53,000	33,000
Proceeds from exercise of warrants		2,000
Net cash provided by financing activities	74,236,000	51,208,000
Net increase in cash and cash equivalents	20,869,000	15,924,000
Cash and cash equivalents, beginning of period	30,688,000	14,764,000
Cash and cash equivalents, end of period	51,557,000	30,688,000
Supplemental disclosures of cash flow information:
Cash paid for interest	312,000	547,000
Supplemental disclosure of non-cash investing and financing activities :
Exchange of common stock for convertible preferred stock, net of issuance costs	24,832,000
Series F Convertible Preferred Stock [Member]
Cash flows from financing activities:
Costs from issuance of Series F	-8,000
Supplemental disclosure of non-cash investing and financing activities :
Fair value of Series F Preferred Stock beneficial conversion feature	14,840,000
Accretion of deemed dividend on Series F Convertible Preferred Stock	($14,840,000)

Organization_and_Description_o

Organization and Description of Business	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Organization and Description of Business	1	Organization and Description of Business
	Overview
	Regado Biosciences, Inc. (the “Company” or “we” or “our” or “us”) is a development stage enterprise incorporated in the State of Delaware on December 19, 2001, operating primarily in Basking Ridge, New Jersey and Durham, North Carolina. We are a biopharmaceutical company that was focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. On August 25, 2014, we announced the permanent termination of enrollment in our REGULATE-PCI phase 3 trial for our lead program, Revolixys™ Kit, formerly known as REG1. The decision was made based on a recommendation from the trial’s Data and Safety Monitoring Board, or DSMB, following their analysis of the data from the first approximately 3,250 patients enrolled in what was intended to be a 13,200-patient trial comparing the safety and efficacy of Revolixys Kit with bivalirudin. Prior to the substantial suspension of our clinical development activities, we were conducting the REGULATE-PCI trial to evaluate Revolixys™ Kit, a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. Revolixys was being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
	In September 2014, we announced that our Board of Directors retained MTS Health Partners, L.P., or MTS, and Cowen & Company, LLC, or Cowen, to act as financial advisors in connection with our exploration of potential business alternatives. In addition, the Company, announced the restructuring activities described in Note 7 to the financial statements to reduce costs following the termination of the REGULATE-PCI trial as part of the Company’s decision to focus resources on three principal activities following the termination of the trial: completion of the final closure of the REGULATE-PCI trial and analysis of the unblinded database from the trial, diligence activities associated with thoroughly exploring potential business alternatives, and the Company’s compliance activities associated with being a public company in good regulatory standing.
	We completed our initial public offering (“IPO”) in August 2013. Inclusive of the underwriters’ exercise of the over-allotment option in connection with the IPO in September 2013, we issued 11,671,500 shares of common stock at a price of $4.00 per share, resulting in net proceeds of approximately $41.1 million, after deducting underwriting discounts of $3.3 million and offering costs of $2.3 million. Pursuant to the IPO, all shares of convertible preferred stock then outstanding automatically converted into an aggregate of 9,396,767 shares of common stock.
	In early 2014, we sold 4,000,000 shares of our common stock at a purchase price of $5.00 per share to certain accredited and institutional investors (the “2014 Private Placement”) for net proceeds of approximately $18.6 million. In March 2014 we effected an exchange of 2,000,000 of the shares of our common stock purchased by certain of the investors in the 2014 Private Placement for 10,000 shares of newly designated Series F Convertible Preferred Stock (the “Series F”), with a stated value of $1,000 per share, each share of which is convertible into 200 shares of our common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting our common stock).
	In April 2014, we consummated an underwritten public offering of 10,000,000 shares of our common stock (the “April 2014 Offering”) at a price of $6.00 per share or $5.64 per share after deducting underwriting discounts and commissions. Upon the underwriters’ exercise of the over-allotment option in connection with this offering, we issued an additional 279,461 shares of common stock resulting in total net proceeds to us of approximately $57.5 million after deducting underwriting discounts of $3.7 million and offering costs of $0.5 million.
	We are not profitable and do not expect to be profitable in the foreseeable future. We have suffered negative cash flows from operating activities of $52.7 million for the year ended December 31, 2014. We have an accumulated deficit of approximately $212.1 million for the year ended December 31, 2014. We have devoted most of our financial resources to research and development, including our preclinical development activities and clinical trials. We have not completed development of any product candidate and we have therefore not generated any revenues from product sales. Since we have ceased our product development activities, we will not have any revenues for the foreseeable future. Also, we will continue to incur expenses from the wind down of the clinical operations and general and administrative costs associated with running the company. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. As of December 31, 2014, we had approximately $51.6 million of cash and cash equivalents. In September 2014, we implemented a workforce reduction plan described in Note 7 to the financial statements and other cost-cutting measures.
	Recent Developments
	On January 14, 2015, the Company announced that it had entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Tobira Therapeutics, Inc., a Delaware corporation (“Tobira”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat liver disease, human immunodeficiency virus, fibrosis and inflammation, Landmark Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company (the “Merger Sub”) and, solely with respect to Section 5.14 of the Merger Agreement, Brent Ahrens, as the agent of Tobira’s stockholders.
	Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company’s stockholders and Tobira’s stockholders, the Merger Sub will be merged with and into Tobira (the “Merger”), with Tobira surviving the Merger as a wholly-owned subsidiary of the Company. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
	At the effective time of the Merger, but subject to the escrow provisions described below: (a) each outstanding share of Tobira’s common stock will be converted into and exchanged for the number of shares of the Company’s common stock (the “Company Common Stock”) equal to the exchange ratio described below; (b) each outstanding Tobira stock option will be assumed by the Company; and (c) certain warrants to acquire Tobira capital stock will be assumed by the Company.
	Under the exchange ratio formula in the Merger Agreement, immediately after the Merger, but excluding the effect of any financing (as described below), the former Tobira securityholders are expected to own approximately 68% of the aggregate number of shares of the Company Common Stock, and the stockholders of the Company immediately prior to the Merger (the “Company Stockholders”) are expected to own approximately 32% of the aggregate number of shares of the Company Common Stock (on a fully diluted basis). This exchange ratio will be adjusted to the extent the Company’s net cash at closing is greater or less than $38 million.
	Following the Merger, Tobira’s Chief Executive Officer, Laurent Fischer, M.D., will be the Company’s Chief Executive Officer, and the Company’s corporate headquarters will be relocated to 701 Gateway Blvd, Suite 300, South San Francisco, CA 94080. Additionally, following the Merger, the board of directors of the Company will consist of nine seats and will be comprised of six representatives of Tobira and three representatives of the Company, with the Company’s current chairman of the board of directors, Dennis Podlesak, continuing to act as chairman of the board of the Company following the Merger.
	The Merger Agreement contains customary representations, warranties and covenants made by the Company and Tobira, including covenants relating to obtaining the requisite approvals of the stockholders of the Company and Tobira, indemnification of directors and officers, the Company’s and Tobira’s conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger and a covenant by the Company to, following the closing of the Merger, file a registration statement on Form S-3 to register the resale of the shares of Company Common Stock issued pursuant to the Merger Agreement.

	The authorization and issuance of the shares of Company Common Stock in the Merger and in the financing described below, amendments of the Company charter related to changing the name of the Company and a potential five to one reverse stock split are subject to approval by the Company’s stockholders. The Merger is subject to other customary closing conditions, including, among other things, the accuracy of the representations and warranties, subject to certain materiality qualifications, compliance by the parties with their respective covenants and no law or order preventing the Merger and related transactions.
	The Merger Agreement may be terminated by either party under certain circumstances, including, among others: (i) if the closing has not occurred by the six-month anniversary of the Merger Agreement; (ii) if a court or other governmental entity has issued a final and non-appealable order prohibiting the closing; (iii) if the Company’s or Tobira’s stockholders fail to approve the transaction; (iv) upon a material uncured breach by the other party that would result in a failure of the conditions to the closing; or (v) in the event of a material adverse event. Upon termination of the Merger Agreement for a party’s failure to obtain the approval of its stockholders, such party is obligated to pay the other party a termination fee of $1 million plus reimburse the other party’s fees and expenses up to $250,000. If such party enters into an agreement relating to an Acquisition Transaction (as defined in the Merger Agreement) or consummates an Acquisition Transaction within 12 months following a termination for the failure to obtain stockholder approval, such party is obligated to pay an additional $1 million to the other party. In addition, if the Merger Agreement is terminated due to certain breaches of the Merger Agreement, the breaching party is obligated to reimburse up to $250,000 of the other party’s fees and expenses.

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2	Basis of Presentation and Summary of Significant Accounting Policies

	Principles of Consolidation and Basis of Presentation

	In March 2013, we incorporated Regado Biosciences Europe Limited, a wholly owned subsidiary registered in England and Wales, in order to establish a legal presence in the European Union (EU) for the purpose of conducting clinical trials in the EU. Regado Biosciences Europe Limited had no operations during the years ended December 31, 2014 or 2013.

	The accompanying consolidated financial statements include the accounts of Regado Biosciences, Inc. and its wholly owned subsidiary, Regado Biosciences Europe Limited. There were no significant intercompany accounts or transactions that needed to be eliminated in consolidation. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.

	Liquidity

	Our financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Operations since inception have consisted primarily of developing and acquiring product technologies and securing financing.

	The accompanying financial statements have been prepared assuming that we will operate as a going concern. We have had negative cash flows from operating activities of $52.7 million for the year ended December 31, 2014. Prior to our initial public offering (“IPO”), we were funded primarily through the issuance of preferred stock and debt. We will continue to closely monitor and analyze expenses and make adjustments as necessary to prioritize business operations. Following the restructuring described in Note 7, and assuming that a transaction involving a potential business alternative is not consummated, we believe that the net proceeds from our recent common stock offerings to new and existing investors (see Note 10) will be sufficient for us to fund our reduced operations for the foreseeable future.

	Reclassifications

	Certain amounts in the December 31, 2013 consolidated balance sheet and statements of cash flows have been reclassified for comparative purposes to conform to the current year presentation. This reclassification did not have any impact on our loss from operations or net loss for the year ended December 31, 2013 or on total assets as of December 31, 2013.



	Use of Estimates

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

	Fair Value of Financial Instruments

	The carrying amount of certain of our financial instruments, including cash and cash equivalents, and accounts payable approximate fair value due to the short maturities of those financial instruments. In conjunction with the refinancing of our long term debt in May 2013, we were required to recognize a warrant liability at December 31, 2014 and 2013 that is required to be measured at fair value on a recurring basis (see Note 3).

	Our valuation of financial instruments is based on a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.

	Cash and Cash Equivalents

	We consider all interest-bearing investments due on demand and all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents included cash of $1.7 million and $363,000 at December 31, 2014 and 2013, respectively. Cash and cash equivalents at December 31, 2014 and 2013 also included investments of $49.9 million and $30.3 million, respectively, in money market funds invested in U.S. Treasury securities with original maturities of less than three months. Cash deposits are held in federally insured financial institutions in the United States of America. We maintain cash in accounts which are in excess of federally insured limits.

	Segment and Geographic Information

	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment and all of the Company’s operations were in North America during 2014 and 2013.

	Clinical Trial Supplies

	Historically, we capitalized materials that were to be used in our REGULATE-PCI clinical trial that had an alternative future use in either ongoing or future clinical research or development projects. Clinical trial supplies may comprise material used to manufacture active pharmaceutical ingredients (“API”) used to develop our product candidates, in-process or completed API, in-process or completed unlabeled finished drug product and labeled finished drug product. With the termination of the REGULATE-PCI trial and suspension of development activities we have expensed these supplies.

	As of December 31, 2014 we expensed all clinical trial supplies. This resulted in expenses of $8.2 million, which are included in R&D expenses for the year ended December 31, 2014. As of December 31, 2013, clinical trial supplies included in other current assets were $4.6 million of which $1.6 million and $3.0 million represented API held at the third party storage facility and drug product located at depots, respectively.



	Clinical Agreements

	We entered into various clinical trial agreements with academic research organizations (“AROs”) and clinical research organizations (“CROs”) for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. Costs for ARO and CRO contracts are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred; such costs are charged to research and development expense in the accompanying consolidated statements of comprehensive loss. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Upfront contract signing fees are amortized over the life of the respective contract.

	In general, our ARO and CRO service agreements permit either party to terminate at will, although we would continue to be responsible for payment of all services completed (or pro-rata completed) at the time of notice of termination, plus any non-cancellable expenses that have been entered into by the ARO and CRO on the Company’s behalf. Accordingly, such expenses would be accrued at time of contract termination and any prepaid expenses and unamortized advance payments would be expensed, accordingly.

	All upfront and contract signing costs were applied to outstanding invoices or expensed during the year ended December 31, 2014. Prepaid expenses on the December 31, 2013 consolidated balance sheet included $1.1 million related to clinical agreements. Other non-current assets at December 31, 2013 included $4.5 million of upfront payments which were applied to final invoices as required under the respective contract.

	Value Added Taxes

	We are charged value added taxes on purchases, made on the Company’s behalf by a CRO, of certain clinical supplies from manufacturers in foreign jurisdictions. As of December 31, 2014 and 2013, the Company had recorded $1.2 million as a VAT receivable and $780,000 as a VAT liability in the accompanying consolidated balance sheet within other current assets and accrued expenses, respectively. There was no impact on our loss from operations or net loss for the year ended December 31, 2014 and 2013 related to VAT.

	Property and Equipment

	Property and equipment consists primarily of laboratory and computer equipment and furniture, which are recorded at cost and depreciated using the straight-line method over their estimated useful lives, ranging from two to five years. Amortization for leasehold improvements is computed using the straight-line method over the estimated useful lives of the assets or over the term of the related leases, whichever is shorter.

	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is credited or charged to income. Repairs and maintenance costs are expensed as incurred.

Intangible Assets and Impairment of Long-lived Assets

The Company’s policy is to file patent application(s) to protect technology, inventions and improvements that are considered important to the development of its business. The patent positions of technology companies, including the Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. Upon receipt of a patent grant, the respective costs are amortized over the remaining life of the patent.

The Company amortizes license agreements over the stated contractual life.

We perform a quarterly review of finite-lived identified intangible assets to determine whether facts and circumstances indicate that the useful life is shorter than we had originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess recoverability by comparing the projected undiscounted net cash flows associated with the related assets or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If an asset’s useful life is shorter than originally estimated, we accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. For the year ended December 31, 2014, management has determined that the carrying value of the patents is impaired. As a result, the Company recognized an impairment loss of approximately $2.1 million for the year ended December 31, 2014. No such impairment was recognized for the year ended December 31, 2013 except for expense recognized for expired and abandoned patents totaling $371,000. Such expenses are included in research and development expenses in the accompanying consolidated statements of comprehensive loss.

Research and Development

Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, license and patent amortization and related impairment, consultants central laboratories and clinical research organizations, including costs incurred in connection with our clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include overhead costs related to facilities, depreciation, insurance, and small supplies that are not allocated to specific product candidates or indications. R&D costs are expensed as incurred.

Stock-based Compensation

In accordance with FASB Accounting Standards Codification (“ASC”) Topic 718, Stock Compensation, as modified or supplemented, we measure compensation cost for share-based payment awards granted to employees and non-employee directors at fair value using the Black-Scholes option-pricing model. We recognize compensation expense on a straight-line basis over the service period for awards expected to vest. Share-based compensation cost related to share-based payment awards granted to non-employees is adjusted each reporting period for changes in the fair value of our common stock until the measurement date. The measurement date is generally considered to be the date when all services have been rendered or the date that options are fully vested.

Series F Convertible Preferred Stock

The Series F convertible preferred stock was deemed to have a beneficial conversion feature (a “BCF”). See Note 10 for further detail regarding the accounting for the Series F convertible preferred stock and this feature.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and warrants.

Recent Accounting Pronouncements

In June of 2014 the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU 2014-10”), Development Stage Entities (Topic 915) “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of comprehensive loss, cash flows, and changes in stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. We have elected to early adopt the provisions of ASU 2014-10 for the current period presented. Other than the changes in presentation noted above, the adoption of ASU 2014-10 did not have significant impact on our results of operations, financial condition or cash flows.



In August 2014, FASB issued ASU 2014-15-Presentation of Financial Statements-Going Concern (ASC Subtopic 205-40): “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The update requires management to assess a company’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. All entities are required to apply the new requirements in annual periods ending after December 15, 2016, and interim periods thereafter. Early application is permitted. As such, we are required to adopt these provisions for the annual period ending December 31, 2016. We are currently evaluating the impact of FASB ASU 2014-15 but we do not expect the adoption thereof to have a material effect on the Company’s financial statements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
Fair Value of Financial Instruments	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3	Fair Value of Financial Instruments
	The following table (in thousands) sets forth our assets and liabilities that were measured at fair value on a recurring basis at December 31, 2014 and 2013 by level within the fair value hierarchy. As required by ASC 820-10, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.


			As of December 31, 2014									As of December 31, 2013
	Assets and Liabilities		Quoted Prices			Significant		Significant		Balance as of		Quoted Prices		Significant		Significant		Balance at
			In Active			Other		Unobservable		December 31,		In Active		Other		Unobservable		December 31,
			Markets for			Observable		Inputs		2014		Markets for		Observable		Inputs		2013
			Identical			Inputs		(Level 3)				Identical		Inputs		(Level 3)
			Assets			(Level 2)						Assets		(Level 2)
			(Level 1)									(Level 1)
	Assets:
	Money market funds		$	49,856		$	—	$	—	$	49,856	$	30,325	$	—	$	—	$	30,325
	Total assets at fair value		$	49,856		$	—	$	—	$	49,856	$	30,325	$	—	$	—	$	30,325
	Liabilities:
	Warrant liability		$	—		$	—	$	8	$	8	$	—	$	—	$	19	$	19
	Total liabilities at fair value		$	—		$	—	$	8	$	8	$	—	$	—	$	19	$	19
	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below (in thousands):


	Balance at December 31, 2013		$	19
	Change in fair value recorded as interest income			(68	)
	Change in fair value recorded as interest expense			57
	Balance at December 31, 2014		$	8
	The warrant liability represents our allocation of a portion of the proceeds from the May 2013 Comerica Loan (as defined in Note 9). The allocation of the proceeds from the Comerica Loan was based on the fair value of the warrant liability on the date of grant. We utilized the Binomial pricing model to determine the fair value of the warrant liability. We record changes in the fair value of the warrant liability as interest expense or interest income, as applicable.
	We used significant assumptions in estimating the fair value of the warrant liability including the estimated volatility, risk free interest rate, estimated fair value of the preferred shares, and the estimated life of the warrant. These assumptions were used to establish an expected set of cash flows which were probability-weighted and discounted to present value to determine a fair value.

Property_and_Equipment_net

Property and Equipment, net	12 Months Ended
Property and Equipment, net	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment, net	4	Property and Equipment, net
	Property and equipment consist of the following (in thousands):


			As of December 31,
			2014			2013
	Leasehold improvements		$	—		$	333
	Computer equipment and software			223			184
	Laboratory equipment			—			1,775
	Furniture and equipment			186			27
	Less – Accumulated depreciation			(170	)		(2,211	)
	Property and equipment, net		$	239		$	108
	Depreciation expense for the years ended December 31, 2014 and 2013 was $127,000, and $61,000, respectively.

Intangibles

Intangibles	12 Months Ended
Intangibles	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	5	Intangibles

	Since we have discontinued our clinical trials, have no intention of resuming drug development related to these intangibles and there is no discernible market for such intellectual property, we have recorded an impairment of these intangibles during 2014.

	The following information details the carrying amounts and accumulated amortization of our intangible assets subject to amortization (in thousands):



			As of December 31, 2014								As of December 31, 2013
			Weighted		Gross		Accumulated		Net		Gross		Accumulated			Net
			Average		Carrying		Amortization		Carrying		Carrying		Amortization			Carrying
			Useful Life		Amount				Amount		Amount					Amount
			Remaining
	Identifiable intangible assets:
	Patents			8.0 years	$	—		—		—	$	1,518	$	(383	)	$	1,135
	Product licenses			2.0 years		—		—		—		1,555		(1,424	)		131
	Total			7.8 years	$	—		—		—	$	3,073	$	(1,807	)	$	1,266

	We record amortization of patent and product license costs in research and development expense in the accompanying consolidated statements of comprehensive loss.

	Patents

	Patent costs consist of expenditures incurred for various patent applications. As of December 31, 2013, we had $557,000 of costs related to patents not subject to amortization as they had yet to be granted. We incurred patent costs of approximately $383,000 during the year ended December 31, 2014. We recognized an impairment loss on all patents of approximately $2 million and $371,000 for the years ended December 31, 2014 and 2013, respectively. The 2014 impairment loss was taken as a result of the termination of the clinical trials.

	Product Licenses

	We have primary license agreements with Duke University, Archemix Corporation, and Nektar Therapeutics AL and all of the licenses were being amortized over the stated contractual life. We incurred costs related to product licensing of approximately $7,000 during the year ended December 31, 2014. We recognized an impairment loss of approximately $104,000 and $0 for the years ended December 31, 2014 and 2013, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6	Commitments and Contingencies

	Employment Agreement

	We entered into an employment agreement with our President and Chief Operating Officer which has an effective date of October 2014. The agreement specifies the compensation payable to, and the services to be provided by, the executive. If the agreement should be terminated by us for other than cause, as defined, we are required to pay 12 months of the executive’s base salary and the executive’s target bonus for the year to be paid semi-monthly.

	Clinical Agreements

	We had various clinical trial agreements with AROs and CROs for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. These contracts generally provide for termination on notice (see Note 2—Clinical Agreements). All such contracts have been terminated as of December 31, 2014.



	Milestones and Other Obligations

	Upon the commencement of our REGULATE-PCI trial which occurred in September 2013, we were obligated to make milestone payments of $500,000 to Duke University (“Duke”), and $1.0 million to Archemix Corporation, (“Archemix”). We paid $500,000 of such milestone obligations during the year ended December 31, 2013. The $1.0 million balance was accrued for as of December 31, 2013, and accordingly, was included in research and development expense in the accompanying statement of comprehensive loss for the year ended December 31, 2013. Payment was made during the year ended December 31, 2014. There are no further payments due for milestones and no outstanding obligations as of December 31, 2014.

	We entered into an agreement with MTS Partners L.P. (“MTS”) where MTS would advise us in connection with its consideration, evaluation and/or exploration of potential transactions. The fees would be a non-refundable retainer of $100,000 upon execution of the agreement plus a fee equal to $1.5 million upon the closing of the transaction, with $500,000 payable in the form of public company securities. The $100,000 retainer was paid during the year ended December 31, 2014. The $1.5 million payment will be paid if we consummate a transaction, including the pending merger with Tobira.

	We entered into an agreement with Cowen and Company, LLC (“Cowen”) where Cowen has been engaged to act as a financial advisor to us in connection with the proposed merger transaction with Tobira. A cash fee of $500,000 is due when Cowen informs the Board of Directors of the Company that it is prepared to render its first opinion. This amount is due without regard to whether the transaction is consummated. In the event of a subsequent opinion, Cowen shall be paid $250,000 in common stock of the Company. If the transaction is consummated, Cowen shall be paid a transaction fee at the closing of the transaction of $250,000 payable in common stock. There have been no payments made for the year ended December 31, 2014.

	License Agreements

	In December 2012, in connection with its Series E Preferred Stock financing, we entered into a Technology Transfer Agreement (the “Tech Transfer Agreement”) with Domain Russia Investments Limited or DRI. In accordance with the terms of the Tech Transfer Agreement, in May 2013 we entered into a Clinical Development and Collaboration Agreement with NovaMedica pursuant to which we agreed to assist NovaMedica in the development and commercialization of our product candidates in the Covered Territory, as defined.

	Operating Leases

	During 2014, we maintained three separate office locations:

	We rent an administrative office space in Durham, North Carolina (the “Durham Office Lease”) under an operating lease agreement effective May 1, 2013, with annual lease obligations of $39,000, $40,000 and $41,000 for years one through three, respectively, for 36 months.

	In April 2007, we entered into an operating lease for 8,495 square feet of laboratory space in Durham, North Carolina. The lease expired July 31, 2012 and subsequent thereto we were on a month-to-month basis with base rent of $11,000 per month. In December 2013 the Company signed a new one year lease for such space with base rent of approximately $13,000 per month and such lease was not renewed at December 31, 2014. An initial letter of credit of $115,000 was given to the lessor for use of the facility, and the letter of credit was reduced to $46,000 on the fourth anniversary date of the lease. This lease has been terminated and the letter of credit has been cancelled.

	In April 2014, we entered into a 6-year lease agreement for 18,467 square feet of administrative office space at 106 Allen Road in Basking Ridge, NJ. The total contractual obligation is $2.4 million. This space is being actively marketed.

	Rent expense related to operating leases was $478,000 and $464,000 for the years ended December 31, 2014 and 2013, respectively.

	Future minimum aggregate payments under non-cancelable lease obligations as of December 31, 2014 are as follows (in thousands):



	For the year ending December 31:		Amount
	2015		$	315
	2016			389
	2017			472
	2018			489
	2019			498
	thereafter			291

	Total minimum lease payments		$	2,454


	Legal Proceedings

	On July 10, 2014, the first of two purported securities class action lawsuits was commenced in the United States District Court for the District of New Jersey, naming as defendants us and certain of our officers and directors. The lawsuits, which were consolidated on September 26, 2014, alleged violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by us related to our Phase 3 trial of Revolixys in patients undergoing certain percutaneous coronary intervention procedures. Plaintiffs alleged, among other things, that we failed to disclose facts related to the potential risk of several allergic reactions following the administration of Revolixys and therefore made false or misleading statements about Revolixys’ safety. This consolidated lawsuit was dismissed without prejudice on December 10, 2014.

	On February 2, 2015, a purported shareholder of the Company filed a putative class-action lawsuit (captioned Maiman v. Regado Biosciences, Inc., Case No. 10606-CB) in the Court of Chancery for the State of Delaware, challenging the proposed stock-for-stock Merger of the Company with Tobira. The complaint names as defendants: (i) each member of the Company’s Board of Directors, (ii) the Company, (iii) Tobira, and (iv) Landmark Merger Sub Inc. Plaintiff alleges that the Company’s directors breached their fiduciary duties to the Company’s stockholders by, among other things, (a) agreeing to merge the Company with Tobira for inadequate consideration, (b) implementing a process that was distorted by conflicts of interest, and (c) agreeing to certain provisions of the Merger Agreement that are alleged to favor Tobira and deter alternative bids. Plaintiff also generally alleges that the entity defendants aided and abetted the purported breaches of fiduciary duty by the directors. Plaintiff seeks an injunction against the consummation of the Merger and an award of costs and expenses, including a reasonable allowance for attorneys’ and experts’ fees. The Company believes the litigation is without merit.

	In addition, from time to time and in the ordinary course of business, we are subject to various other claims, charges and litigation. Class action lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of these lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of these suits and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. We have a multi-layer Directors and Officers (“D&O”) insurance policy which will provide reimbursement of the defense costs. There is not a guarantee that our insurance limits will be sufficient to cover all incurred expenses. We currently are not able to estimate the possible cost to us from these matters, as this lawsuit is currently at an early stage, and we cannot be certain how long it may take to resolve this matter or the possible amount of any damages that we may be required to pay. We have not established any reserve for any potential liability relating to this lawsuit. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring	7	Restructuring
	On September 24, 2014, the Company announced a workforce reduction plan to reduce costs following the termination of the REGULATE-PCI trial. Pursuant to the workforce reduction plan, the Company eliminated 88% of the Company’s workforce, or 28 of our 32 full-time employees, across all operational sites. Affected employees were offered separation benefits, including severance payments, and temporary healthcare coverage assistance.
	Effective September 26, 2013, we reduced our workforce by eliminating 5 of our then 32 full-time employees. The majority of the affected employees worked in drug discovery roles at our laboratory facility in North Carolina. The goal of our reduction in workforce was to enable us to focus management and financial resources on advancing our lead product candidate, REG1, in our REGULATE-PCI trial.
	There was $3.3 million of severance expense incurred in 2014 and $2.6 million remains unpaid at December 31, 2014. There was $667,000 of severance expense incurred in 2013 and $417,000 remained unpaid at December 31, 2013.
	We have accrued $4.6 million in connection with the wind down of various operational activities for the company including severance, final payments and anticipated but identified close down expenditures. In our estimation, our accrual for these costs is reasonable, based on the best information currently available, although the resolution of certain contingencies could result in ultimate expenditures up to an estimated maximum amount of $7.0 million.

Accrued_Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	8	Accrued Expenses

	The components of accrued expenses are as follows (in thousands):



			As of December 31,
			2014		2013
	Accrued license milestones		$	—	$	1,000
	Accrued obligations under clinical contracts			—		1,957
	Accrued restructuring costs			4,591		—
	Accrued legal and professional services			276		152
	Accrued VAT expenses			780		780
	Accrued interest			21		24
	Accrued compensation and benefits			140		1,225
	Accrued expenses, other			490		386

	Total accrued expenses		$	6,298	$	5,524

Longterm_Debt

Long-term Debt	12 Months Ended
Long-term Debt	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-term Debt	9	Long-term Debt

	In May 2011, we entered into a loan and security agreement with MidCap Financial SBIC, LP pursuant to which we borrowed a total of $6.0 million, at the stated rate of LIBOR, at a 2% rate floor, plus 8% spread per annum. The loan was payable in monthly installments beginning May 2012 through August 2014. Our assets (including intellectual property) were collateral for the borrowings, and we were required to pay a 3% final payment of $180,000 regardless of when the loan was paid in full. The final installment on the loan and final payment were made in 2013.

	On May 13, 2013, we secured a venture debt loan with Comerica Bank (the “Comerica Loan”). We borrowed $4.5 million (“Tranche One”), and the proceeds of the loan were utilized to repay all amounts due to MidCap Financial SBIC, LP. The Comerica Loan bears interest at Comerica’s Prime Reference Rate (as defined in the Loan Agreement) subject to a floor of 30 day LIBOR plus 250 basis points plus 4.0%, or 7.25% as of December 31, 2014. The terms allow for an interest only period of 15 months, and the remaining principal and interest will be repaid starting September 2014 over a nine-month period (24 months in total), maturing in 2015. Upon (i) Comerica’s receipt of evidence satisfactory to Comerica that the 1,000 patient interim analysis in the REGULATE-PCI study was successful and performed by April 30, 2014 and (ii) our completion of the IPO and receipt of net proceeds of at least $50.0 million prior to June 30, 2013, we had the option to borrow an additional $4.0 million in the second tranche, or (“Tranche Two”). Since the latter of the Tranche Two conditions was not satisfied, Tranche Two is solely at the discretion of Comerica. We have not, and have no intention of, borrowing under Tranche Two. At December 31, 2014 and 2013, the balance outstanding was approximately $2,629,000 and $4,452,000 respectively.

	Interest expense recorded related to the Comerica Loan, including changes in fair value of warrants, was approximately $575,000 and $355,000 for the years ended December 31, 2014 and 2013, respectively. Interest expense recorded related to the MidCap Loan was $0 and $325,000 for the years ended December 31, 2014 and 2013, respectively.

	In connection with the funding of Tranche One, we issued to Comerica a warrant to purchase 156,250 shares of the Series E Preferred Stock at a price of $0.72 per share, or the Warrant Price, subject to adjustment for stock splits, combinations, reclassifications or exchanges and certain dilutive issuances. After giving effect to our IPO and reverse stock split, the warrant was adjusted to a warrant to purchase 9,356 shares of our common stock at a price of $12.02 per share (see Note 4).



	Under the terms of the Loan Agreement, we granted Comerica a first priority security interest in substantially all of our assets other than our intellectual property. The Loan Agreement does not contain any ongoing financial covenants.

	The Loan Agreement provides that upon the occurrence of and during a period of default as defined therein, interest on the loan will accrue at a penalty rate. Upon the occurrence and during the continuance of a default, or a material adverse event, Comerica may, at its election, make all obligations under the Loan Agreement immediately due and payable, cease advancing money or extending credit, exercise its right of setoff, foreclose on our assets, dispose of collateral at a public or private sale, and exercise any other remedies available to a secured creditor at law or in equity. Management has discussed the loan agreement with Comerica, and Comerica has indicated they are not planning to exercise their call option as the Company has adequate cash on the balance sheet and is submitting required capital repayments.



	The Comerica debt is summarized as follows (in thousands):



			As of December 31,
			2014			2013
	Principal due in 2014		$	—		$	2,000
	Principal due in 2015			2,500			2,500
	Less: unamortized discount			(13	)		(103	)
	Plus – fees due at closing (1)			142			55

	Total Short Term Debt			2,629			4,452
	Less: current portion			(2,629	)		(2,000	)

	Long-term debt, net		$	—		$	2,452



	-1	On the date that all of the principal and interest of the Comerica Loan become due and payable, we must pay an end of term fee of $173,000 (the “Final Fee”). The Final Fee is being accreted to interest expense over the term of the Comerica Loan

	In accounting for the Comerica Loan, the loan was separated into debt and warrant liability components. We utilized the Binomial pricing model to determine the fair value of the warrant liability component (see Note 3). The carrying amount of the debt component was determined by deducting the fair value of the warrant liability component from the par value of the Comerica Loan as a whole. The excess of the principal amount of the Comerica Loan component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the term of the loan. The warrant liability component is re-measured at each reporting date and changes in the fair value of the warrant liability are recorded as interest expense or interest income, as applicable.

	In accounting for the transaction costs related to the issuance of the Comerica Loan, we allocated the total costs incurred to the debt and warrant liability components of the Comerica Loan based on their relative values. Transaction costs attributable to the debt component are amortized to interest expense over the term of the Comerica Loan, and transaction costs attributable to the warrant liability component were immediately expensed.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	10	Stockholders’ Equity (in thousands except share and per share amounts)

	Post IPO Common and Preferred Stock Authorized Shares

	Effective with the IPO, pursuant to the Company’s Sixth Amended and Restated Certificate of Incorporation (the “Restated Certificate”) the Company is authorized to issue two (2) classes of shares to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares of capital stock that the Company is authorized to issue is 501,000,000 shares of capital stock, of which (i) 500,000,000 shares are designated as common stock, par value $0.001 per share (the “Common Stock”), and (ii) 1,000,000 shares are class designated as preferred stock, par value $0.001 per share. (the “Preferred Stock”).

	Prior to the IPO the Company was authorized to issue two (2) classes of shares to be designated, respectively, “Pre-IPO Common Stock” and “Pre-IPO Preferred Stock.” The total number of shares of capital stock that the Company was authorized to issue was 698,363,299 shares. The total number of shares of Pre-IPO Common Stock the Company was authorized to issue was 500,000,000 shares, $0.001 par value per share. The total number of shares of Preferred Stock the Company was authorized to issue was 198,363,299 shares, $0.001 par value per share, of which (a) 5,798,178 shares were to be designated Series A Preferred Stock (the “Series A Preferred Stock”); (b) 16,666,665, shares were to be designated Series B Preferred Stock (the “Series B Preferred Stock”); (c) 17,037,037 shares were to be designated Series C Preferred Stock (the “Series C Preferred Stock”), (d) 71,666,667 shares were to be designated Series D Preferred Stock (the “Series D Preferred Stock”), and (e) 87,194,752 shares were to be designated Series E Preferred Stock (the “Series E Preferred Stock,” and together with the Series A Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, and the Series D Preferred Stock, the “Pre-IPO Preferred Stock”).



	Each holder of record of Common Stock shall have one vote for each share of Common Stock which is outstanding in his, her or its name on the books of the Corporation on all matters on which stockholders are entitled to vote generally. Except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to the Restated Certificate (including any certificate of designation relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Restated Certificate (including any certificate of designation relating to any series of Preferred Stock) or pursuant to the General Corporation Law of the State of Delaware. Except as otherwise required by law, holders of any series of Preferred Stock shall be entitled to only such voting rights, if any, as shall expressly be granted thereto by the Restated Certificate (including any certificate of designation relating to such series of Preferred Stock).

	Subject to applicable law and the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the payment of dividends, dividends may be declared and paid or set apart for payment upon the Common Stock out of any assets or funds of the Corporation legally available for the payment of dividends, but only when and as declared by the Board of Directors or any authorized committee thereof.

	Upon the dissolution, liquidation or winding up of the Company, after payment or provision for payment of the debts and other liabilities of the Company and subject to the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the distribution of assets of the Company upon such dissolution, liquidation or winding up of the Company, the holders of Common Stock shall be entitled to receive the remaining assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held by them.

	The Board of Directors is authorized, by resolution or resolutions, to provide, out of the unissued shares of Preferred Stock, for one or more series of Preferred Stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, and the powers (including voting powers, if any), preferences and relative, participating, optional and other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series of Preferred Stock. The powers, preferences and relative, participating, optional and other special rights of, and the qualifications, limitations or restrictions thereof, of each series of Preferred Stock, if any, may differ from those of any and all other series at any time outstanding

	2014 and 2013 Transactions

	In April 2014, we consummated an underwritten public offering of 10,000,000 shares of our common stock (the “April 2014 Offering”) at a price of $6.00 per share or $5.64 per share after deducting underwriting discounts and commissions. Upon the underwriters’ exercise of the over-allotment option in connection with this offering, we issued an additional 279,461 shares of common stock resulting in total net proceeds to us of approximately $57.5 million after deducting underwriting discounts of $3.7 million and offering costs of $0.5 million. In connection with the April 2014 Offering, the Company, each of its officers and directors and certain stockholders agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock for a 90-day period after the offering, except with the prior written consent of the underwriters. This restriction has now expired.

	Pursuant to the IPO all shares of Series A – E Preferred Stock then outstanding automatically converted into an aggregate of 9,396,767 shares of common stock.

	Per the Series E Preferred Stock financing agreement executed on December 18, 2012, a second financing tranche of $10.3 million for 14,320,168 shares of Series E Preferred Stock took place on March 22, 2013. The agreement also provided that a third financing tranche of $17.8 million for 24,770,476 shares of Series E preferred stock would take place on or before January 17, 2014. However, pursuant to the terms of a Termination Agreement entered into by the parties to the Series E Purchase Agreement, our obligation to sell additional shares of Series E Preferred Stock to the investors and the obligations of the investors to purchase additional shares of Series E Preferred Stock terminated immediately prior to the consummation of the IPO and no additional shares of Series E Preferred Stock will be sold pursuant thereto.



	During the first quarter of 2014, we sold 4,000,000 shares of our common stock at a purchase price of $5.00 per share to certain accredited and institutional investors (the “2014 Private Placement”), raising an aggregate of $20.0 million before sales agency fees and offering costs of approximately $1.4 million. . In connection with this financing, the Company entered into a securities purchase agreement, pursuant to which it agreed to register the resale of the shares of common stock issued in the financing.

	On March 21, 2014, we entered into an exchange agreement, (“Exchange Agreement”), with Biotechnology Value Fund, LP, Biotechnology Value Fund II, LP and Investment 10, LLC (“the Exchanging Stockholders”) pursuant to which we effected an exchange (“the Exchange”) of the 2,000,000 shares of our common stock purchased by the exchanging stockholders in our 2014 Private Placement for 10,000 shares of newly designated Series F Convertible Preferred Stock (“Series F”) with a stated value of $1,000 per share, each share of which is convertible into 200 shares of our common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting our common stock).

	The preferred stock was issued without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.

	Series F Convertible Preferred Stock Terms

	Pursuant to the terms of the Series F, the exchanging stockholders have the right to convert the Series F into 2,000,000 shares of our common stock, determined by dividing the stated value of $1,000 per share by the conversion price of $5.00 per share, subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting our common stock; provided, however, that the preferred stock cannot be converted by the exchanging stockholders if, after giving effect thereto, the exchanging stockholders would beneficially own more than 9.99% of our common stock, calculated as provided in the certificate of designation establishing the preferred stock, subject to certain exceptions.

	The holders of the preferred stock will not have the right to vote on any matter except to the extent required by Delaware law.

	Series F convertible preferred shares are entitled to dividends in the same form as dividends actually paid on shares of common stock other than dividends in the form of common stock.

	Upon the execution of a fundamental transaction which effects a merger or other change of control transaction of the Company, a holder will have the right to receive, upon any subsequent conversion of a share of Series F (in lieu of conversion shares) for each issuable conversion share, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such fundamental transaction if it had been, immediately prior to such fundamental transaction, the holder of the shares of common stock into which such holder’s shares of Series F is then convertible.

	Accounting for the Series F Convertible Preferred Stock

	Each share of the Series F is convertible into 200 shares of common stock at any time at the option of the holder, subject to adjustment, and the beneficial ownership limitation provision noted above. The Company has recorded the Series F in equity. The initial carrying value of the Series F was $24.8 million. Upon completion of the Exchange, the conversion option of the Series F was immediately exercisable; therefore, the $14.8 million discount related to the BCF was immediately accreted to Series F, resulting in an increase in the carrying value of the Series F by $14.8 million. For the year ended December 31, 2014, the value of the BCF of $14.8 million was included in the Company’s net loss applicable to common shareholders (see Note 14).

	As the Series F are considered participating securities, the Series F participates in the earnings or losses of the Company. Consequently, net losses were adjusted for the deemed distributions relating to the BCF and losses attributable to preferred stockholders to calculate the net loss attributable to common stockholders for the year ended December 31, 2014.



	Warrants

	See Notes 3 and 9 regarding our issuance of a warrant for Series E Preferred Stock in connection with obtaining the Comerica Loan. As of December 31, 2014 and 2013, we had 9,356 and 16,332 warrants outstanding, respectively, that were exercisable into common shares at a weighted average price of $12.02 and $6.96 per share, respectively, at the option of the warrant holder. During the year ended December 31, 2014, warrants for 6,976 shares of common stock were exercised at an exercise price of $0.17.

Stock_Based_Compensation

Stock Based Compensation	12 Months Ended
Stock Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Based Compensation	11	Stock Based Compensation

	Equity Compensation Plans

	The 2013 Equity Compensation Plan (the “2013 Plan”) adopted by our Board of Directors in May 2013, became effective upon consummation of the IPO in August 2013. There are 4,408,369 common shares authorized for future issuance under the 2013 Plan of which 937,228 were available as of December 31, 2014. Upon effectiveness of the 2013 Plan, stock options outstanding under the 2004 Equity Compensation Plan (the “2004 Plan”) to acquire 1,406,910 shares of our common stock were assumed under the 2013 Plan, leaving stock options to acquire 34,342 shares of our common stock outstanding under the 2004 Plan. There will be no further awards made under the 2004 Plan.

	The 2013 Plan includes an “evergreen provision” that allows for an annual increase in the number of shares of common stock available for issuance under the 2013 Plan. The annual increase will be added on the first day of each fiscal year starting January 1, 2014, inclusive, and will be equal to five percent of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year as determined by the board of directors (the Board). The Board may act prior to the first day of any calendar year, to provide that there shall be no increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year shall be a lesser number of shares of Common Stock than would otherwise occur. On January 1, 2014 another 1,065,530 shares became available for grant under this evergreen provision, increasing the number of shares authorized for issuance under the 2013 Plan from 3,342,839 shares to a total of 4,408,369 shares as of December 31, 2014. On January 1, 2015 another 1,680,461 options became available for grant under this evergreen provision.

	Stock Options

	We use the Black-Scholes-Merton option pricing model to determine the fair value of our stock options. The determination of the fair value of stock-based payment awards on the date of grant using an option pricing model is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, risk-free interest rate, actual employee exercise behaviors and expected dividends.



	The following table shows the weighted average assumptions used to value stock options on the date of grant, as follows:



			Year ended December 31,
			2014								2013
			Employee				Non-Employees				Employee				Non-Employees
	Expected stock price volatility			55.17	%			62.71	%			46	%			45.3	%

	Risk-free interest rate			1.33	%			0.1	%			1.04	%			0.37	%

	Expected life of option (in years)			3.2				0.6				3.69				2

	Estimated dividend yield			0	%			0	%			0	%			0	%

	Weighted-average grant date fair value per share		$	0.02			$	0.02				1.91				1.49

	Expected stock price volatility was calculated based on the weighted-average of historical information of similar public entities. We will continue to use a weighted-average approach using other similar public entities’ volatility information until our historical volatility is relevant to measure expected volatility for future option grants. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The average expected life was determined based on anticipated exercise strategy and cancellation behavior for employees and nonemployees, primarily non-employee directors. Effective in 2013, a forfeiture rate of 1% and 0% was used for employees and nonemployees, respectively. We have not paid and do not anticipate paying cash dividends; therefore, the expected dividend rate was assumed to be 0%.

	The following table summarizes our aggregate Equity Compensation Plan activity:



			Number of				Weighted Average				Weighted Average				Aggregate
			Options				Exercise Price				Contractual				Intrinsic Value (1)
											Term
											(in years)
	Outstanding – January 1, 2014			3,272,847
	Granted			2,162,142
	Exercised			(12,161	)
	Forfeited			(1,428,678	)
	Expired			(155,028	)
	Outstanding – December 31, 2014			3,839,122			$	4.68				6.43			$	50,252

	Exercisable – December 31, 2014			2,067,500			$	5.43				4.99			$	14,657
	Vested and expected to vest at December 31,2014 (2)			3,825,209			$	4.67				6.42			$	49,761


	-1	Intrinsic value is the excess of the fair value of the underlying common shares as of December 31, 2014 over the weighted-average exercise price. A negative intrinsic value indicates the weighted-average exercise price is greater than the fair value of the underlying common shares as of December 31, 2014.
	-2	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

	The total intrinsic value of options exercised during the year ended December 31, 2014 and 2013 was $30,000 and $11,000, respectively.



	The following table summarizes certain information about all options outstanding as of December 31, 2014:



			Options Outstanding								Options Exercisable
Exercise Price		Options				Weighted Average				Options				Weighted Average
		Outstanding				Remaining				Exercisable				Remaining
						Contractual Life								Contractual Life
						(Years)								(Years)

$0.80 - $1.10			837,531				9.9				244,280				9.9

$1.67 - $3.84			260,758				3.5				227,286				2.8

$3.85 - $4.50			721,213				5.9				721,213				5.9

$4.51 - $4.81			1,128,061				5.4				717,203				4

$4.87 - $12.53			891,559				5.2				697,518				4.1

			3,839,122				6.4				2,607,500				5


The following table summarizes certain information about all options outstanding as of December 31, 2013:



		Options Outstanding								Options Exercisable
Exercise Price		Options				Weighted Average				Options				Weighted Average
		Outstanding				Remaining				Exercisable				Remaining
						Contractual Life								Contractual Life
						(Years)								(Years)

$1.67-$3.84			334,921				5.8				254,829				5

$4.00			1,366,760				9.6				4,256				1

$4.51-$4.81			951,961				7.8				626,455				6.7

$4.87-$12.53			619,205				5.2				501,113				4.1


			3,272,847				7.9				1,386,653				5.4


Stock-Based Compensation Expense

In the fourth quarter of 2014, the Company decided to extend the exercise period of certain awards. The Company accounted for the extension of the exercise period as a modification under modification accounting. The Company valued the old awards immediately prior to the modification and the excess value of the new award over that value is recorded as an incremental expense over the vesting period. Additional stock compensation cost expensed in the year ended December 31, 2014 related to the modification was immaterial.

Total stock-based compensation expense recognized based on the total grant date fair value of options vested and expected to vest was approximately $2.0 million and $988,000 for the years ended December 31, 2014 and 2013, respectively. Due to the valuation allowance against our net deferred tax asset, we have never recognized a tax benefit for stock based compensation.

All stock options issued to nonemployees have been recorded at fair value. Options issued to nonemployees in exchange for services have resulted in expenses of $0 and $59,000 during the years ended December 31, 2014 and 2013, respectively.

As of December 31, 2014, approximately $1,030,000 of total unrecognized compensation cost related to unvested share options is expected to be recognized over a weighted-average period of 2.3 years.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2014
Postemployment Benefits [Abstract]
Employee Benefit Plan	12	Employee Benefit Plan
	In 2006, the Company adopted the Regado Biosciences 401k Plan (the Plan). The Plan allows eligible employees to defer up to 87% of their compensation, up to allowable Internal Revenue Service limits. Effective December 19, 2013 the Company elected to match participant elective deferrals in an amount equal to 50% of such elective deferrals on the first 6.0% of each participant’s total compensation for the Plan Year. The Company also declared a retroactive match for the year ended December 31, 2013. The Company’s aggregate 401K match expense for the years ended December 31, 2014 and 2013 was $101,000 and $88,000, respectively.
	The Company has a Special Incentive Plan that provides for retention bonuses to be granted to certain participants in the event of a change of control. No such bonuses were incurred in 2014 or 2013.
	Effective upon the consummation of the IPO, the Company adopted an Employee Stock Purchase Plan (the “ESPP”). Upon effectiveness, up to 96,360 shares of the Company’s common stock may be issued pursuant to the ESPP. There were no shares outstanding under this ESPP as of December 31, 2014 or 2013.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	13	Income Taxes

	Significant components of the Company’s deferred income tax assets and liabilities at December 31, 2014 and 2013, consisted of the following (in thousands):



			2014			2013
	Deferred income tax assets:
	Net operating loss carryforwards		$	78,276		$	53,436
	Property and equipment			8			136
	Stock-based compensation expense			1,403			661
	Accruals			1,700			1,220
	Other			20			44
	Valuation allowance for deferred income tax assets			(81,407	)		(54,999	)

	Net deferred income tax assets			—			498
	Deferred income tax liabilities:
	Patent costs			—			(498	)

	Net deferred income taxes		$	—		$	—


	At December 31, 2014 and 2013, the Company provided a full valuation allowance against its net deferred income tax assets, as management has assessed that the realization of these benefits is not more-likely-than-not. The change in the valuation allowance is primarily attributable to additional net operating loss carryforwards from current year activity.



	The differences between the statutory rate and the effective rate are due to the valuation allowance and other permanent differences, as shown in the table below (dollars in thousands):



			2014						2013
			Tax			Rate			Tax			Rate
	Rate Reconciliation
	Tax at statutory rate		$	(23,489	)		35	%	$	(12,054	)		35	%
	Incentive stock options			19			(0.0	)%		148			(0.4	)%
	Non-deductibles			(19	)		0	%		—			0	%
	State taxes			(2,684	)		4	%		(1,378	)		4	%
	Contribution adjustment			19			(0.0	)%		—			0	%
	Federal NOL adjustment			(2,145	)		3.2	%		—			0	%
	State NOL adjustment			1,655			(2.5	)%		—			0	%
	Other deferred tax asset adjustment			235			(0.3	)%		—			0	%
	Change in valuation allowance			26,408			(39.4	)%		13,002			(37.8	)%
	Other			1			(0.0	)%		282			0.8	%

	Income tax expense reported		$	—			—	%	$	—			—	%


	As of December 31, 2014, the Company had estimated federal and state operating loss carry forwards of approximately $205.6 million and $257.9 million available the offset future federal and state taxable income which begin to expire in 2022 and 2017, respectively. The utilization of the federal net operating loss carry forwards may be subject to limitations under the rules regarding a change in stock ownership as determined by the Internal Revenue Code, and state laws. Section 382 of the Internal Revenue Code of 1986, as amended, imposes annual limitations on the utilization of net operating loss (“NOL”) carry forwards, other tax carry forwards, and certain built-in losses upon an ownership change as defined by that section. In general terms, an ownership change may result from transactions that increase the aggregate ownership of certain stockholders in the Company stock by more than 50 percentage points over a three year testing period (“Section 382 Ownership Change”). If the Company has undergone a Section 382 Ownership change, an annual limitation would be imposed on certain of the Company’s tax attributes, including NOL and capital loss carry forwards, and certain other losses, credits, deductions of tax basis. As of December 31, 2014, the Company has not performed a formal study to determine whether there are Section 382 limitations that apply.

	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. As of the end of 2014 or 2013, the Company did not record a liability for uncertain tax positions because no material positions existed.

	The Company did not have any accrued interest or penalties associated with any unrecognized tax positions at December 31, 2014, and there were no such interest or penalties recognized during the period since inception through December 31, 2014.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
Net Loss Per Share	Dec. 31, 2014
Earnings Per Share [Abstract]
Net Loss Per Share	14	Net Loss Per Share

	In March 2014, the Company issued the Series F with a BCF (See Note 9) and recorded a deemed dividend relating to the BCF of $14.8 million for 2014. The Series F participates in earnings or losses of the Company. Consequently, net losses were adjusted for the deemed distribution relating to the BCF and losses attributable to Series F stockholders to calculate the net loss attributable to common stockholders.



	The following table presents the calculation of basic and diluted net loss per share of common stock attributable to the Company’s common stockholders (in thousands, except share and per share data):



			December 31,
			2014			2013
	Net loss per share:
	Numerator:
	Net loss		$	(67,112	)	$	(34,439	)
	Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock			(14,840	)		—

	Net loss attributable to stockholders			(81,952	)		(34,439	)
	Net loss attributable to preferred stockholders			(3,972	)		—

	Net loss attributable to common stockholders — basic and diluted			(77,980	)		(34,439	)

	Denominator:
	Weighted average common shares outstanding, basic and diluted			30,658,820			7,499,661

	Net loss per share attributable to common stockholders, basic and diluted		$	(2.54	)	$	(4.59	)


	For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to our net loss position. Securities that may potentially dilute earnings per share in the future that have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):



			December 31,
			2014			2013
	Convertible preferred stock			2,000,000			—
	Common stock options			3,839,122			3,272,847
	Warrants			9,356			16,332

	Total			5,848,478			3,289,179

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	15	Subsequent Events

	On January 14, 2015, the Company announced that it had entered into an agreement and Plan of Merger and Reorganization with Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company (See note 1).

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation

	In March 2013, we incorporated Regado Biosciences Europe Limited, a wholly owned subsidiary registered in England and Wales, in order to establish a legal presence in the European Union (EU) for the purpose of conducting clinical trials in the EU. Regado Biosciences Europe Limited had no operations during the years ended December 31, 2014 or 2013.

	The accompanying consolidated financial statements include the accounts of Regado Biosciences, Inc. and its wholly owned subsidiary, Regado Biosciences Europe Limited. There were no significant intercompany accounts or transactions that needed to be eliminated in consolidation. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
Liquidity	Liquidity

	Our financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Operations since inception have consisted primarily of developing and acquiring product technologies and securing financing.

	The accompanying financial statements have been prepared assuming that we will operate as a going concern. We have had negative cash flows from operating activities of $52.7 million for the year ended December 31, 2014. Prior to our initial public offering (“IPO”), we were funded primarily through the issuance of preferred stock and debt. We will continue to closely monitor and analyze expenses and make adjustments as necessary to prioritize business operations. Following the restructuring described in Note 7, and assuming that a transaction involving a potential business alternative is not consummated, we believe that the net proceeds from our recent common stock offerings to new and existing investors (see Note 10) will be sufficient for us to fund our reduced operations for the foreseeable future.
Reclassifications	Reclassifications

	Certain amounts in the December 31, 2013 consolidated balance sheet and statements of cash flows have been reclassified for comparative purposes to conform to the current year presentation. This reclassification did not have any impact on our loss from operations or net loss for the year ended December 31, 2013 or on total assets as of December 31, 2013.


Use of Estimates	Use of Estimates

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments

	The carrying amount of certain of our financial instruments, including cash and cash equivalents, and accounts payable approximate fair value due to the short maturities of those financial instruments. In conjunction with the refinancing of our long term debt in May 2013, we were required to recognize a warrant liability at December 31, 2014 and 2013 that is required to be measured at fair value on a recurring basis (see Note 3).

	Our valuation of financial instruments is based on a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.
Cash and Cash Equivalents	Cash and Cash Equivalents

	We consider all interest-bearing investments due on demand and all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents included cash of $1.7 million and $363,000 at December 31, 2014 and 2013, respectively. Cash and cash equivalents at December 31, 2014 and 2013 also included investments of $49.9 million and $30.3 million, respectively, in money market funds invested in U.S. Treasury securities with original maturities of less than three months. Cash deposits are held in federally insured financial institutions in the United States of America. We maintain cash in accounts which are in excess of federally insured limits.
Segment and Geographic Information	Segment and Geographic Information

	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one operating segment and all of the Company’s operations were in North America during 2014 and 2013.
Clinical Trial Supplies	Clinical Trial Supplies

	Historically, we capitalized materials that were to be used in our REGULATE-PCI clinical trial that had an alternative future use in either ongoing or future clinical research or development projects. Clinical trial supplies may comprise material used to manufacture active pharmaceutical ingredients (“API”) used to develop our product candidates, in-process or completed API, in-process or completed unlabeled finished drug product and labeled finished drug product. With the termination of the REGULATE-PCI trial and suspension of development activities we have expensed these supplies.

	As of December 31, 2014 we expensed all clinical trial supplies. This resulted in expenses of $8.2 million, which are included in R&D expenses for the year ended December 31, 2014. As of December 31, 2013, clinical trial supplies included in other current assets were $4.6 million of which $1.6 million and $3.0 million represented API held at the third party storage facility and drug product located at depots, respectively.
Clinical Agreements	Clinical Agreements

	We entered into various clinical trial agreements with academic research organizations (“AROs”) and clinical research organizations (“CROs”) for the planning, management and execution of clinical trials. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. Costs for ARO and CRO contracts are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred; such costs are charged to research and development expense in the accompanying consolidated statements of comprehensive loss. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Upfront contract signing fees are amortized over the life of the respective contract.

	In general, our ARO and CRO service agreements permit either party to terminate at will, although we would continue to be responsible for payment of all services completed (or pro-rata completed) at the time of notice of termination, plus any non-cancellable expenses that have been entered into by the ARO and CRO on the Company’s behalf. Accordingly, such expenses would be accrued at time of contract termination and any prepaid expenses and unamortized advance payments would be expensed, accordingly.

	All upfront and contract signing costs were applied to outstanding invoices or expensed during the year ended December 31, 2014. Prepaid expenses on the December 31, 2013 consolidated balance sheet included $1.1 million related to clinical agreements. Other non-current assets at December 31, 2013 included $4.5 million of upfront payments which were applied to final invoices as required under the respective contract.
Value Added Taxes	Value Added Taxes

	We are charged value added taxes on purchases, made on the Company’s behalf by a CRO, of certain clinical supplies from manufacturers in foreign jurisdictions. As of December 31, 2014 and 2013, the Company had recorded $1.2 million as a VAT receivable and $780,000 as a VAT liability in the accompanying consolidated balance sheet within other current assets and accrued expenses, respectively. There was no impact on our loss from operations or net loss for the year ended December 31, 2014 and 2013 related to VAT.
Property and Equipment	Property and Equipment

	Property and equipment consists primarily of laboratory and computer equipment and furniture, which are recorded at cost and depreciated using the straight-line method over their estimated useful lives, ranging from two to five years. Amortization for leasehold improvements is computed using the straight-line method over the estimated useful lives of the assets or over the term of the related leases, whichever is shorter.

	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is credited or charged to income. Repairs and maintenance costs are expensed as incurred.
Intangible Assets and Impairment of Long-lived Assets	Intangible Assets and Impairment of Long-lived Assets

	The Company’s policy is to file patent application(s) to protect technology, inventions and improvements that are considered important to the development of its business. The patent positions of technology companies, including the Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. Upon receipt of a patent grant, the respective costs are amortized over the remaining life of the patent.

	The Company amortizes license agreements over the stated contractual life.

	We perform a quarterly review of finite-lived identified intangible assets to determine whether facts and circumstances indicate that the useful life is shorter than we had originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess recoverability by comparing the projected undiscounted net cash flows associated with the related assets or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If an asset’s useful life is shorter than originally estimated, we accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. For the year ended December 31, 2014, management has determined that the carrying value of the patents is impaired. As a result, the Company recognized an impairment loss of approximately $2.1 million for the year ended December 31, 2014. No such impairment was recognized for the year ended December 31, 2013 except for expense recognized for expired and abandoned patents totaling $371,000. Such expenses are included in research and development expenses in the accompanying consolidated statements of comprehensive loss.
Research and Development	Research and Development

	Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, license and patent amortization and related impairment, consultants central laboratories and clinical research organizations, including costs incurred in connection with our clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include overhead costs related to facilities, depreciation, insurance, and small supplies that are not allocated to specific product candidates or indications. R&D costs are expensed as incurred.
Stock-based Compensation	Stock-based Compensation

	In accordance with FASB Accounting Standards Codification (“ASC”) Topic 718, Stock Compensation, as modified or supplemented, we measure compensation cost for share-based payment awards granted to employees and non-employee directors at fair value using the Black-Scholes option-pricing model. We recognize compensation expense on a straight-line basis over the service period for awards expected to vest. Share-based compensation cost related to share-based payment awards granted to non-employees is adjusted each reporting period for changes in the fair value of our common stock until the measurement date. The measurement date is generally considered to be the date when all services have been rendered or the date that options are fully vested.
Series F Convertible Preferred Stock	Series F Convertible Preferred Stock

	The Series F convertible preferred stock was deemed to have a beneficial conversion feature (a “BCF”). See Note 10 for further detail regarding the accounting for the Series F convertible preferred stock and this feature.
Net Loss Per Share	Net Loss Per Share

	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and warrants.
Recent Accounting Pronouncements	Recent Accounting Pronouncements

	In June of 2014 the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU 2014-10”), Development Stage Entities (Topic 915) “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of comprehensive loss, cash flows, and changes in stockholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. We have elected to early adopt the provisions of ASU 2014-10 for the current period presented. Other than the changes in presentation noted above, the adoption of ASU 2014-10 did not have significant impact on our results of operations, financial condition or cash flows.



	In August 2014, FASB issued ASU 2014-15-Presentation of Financial Statements-Going Concern (ASC Subtopic 205-40): “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The update requires management to assess a company’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. All entities are required to apply the new requirements in annual periods ending after December 15, 2016, and interim periods thereafter. Early application is permitted. As such, we are required to adopt these provisions for the annual period ending December 31, 2016. We are currently evaluating the impact of FASB ASU 2014-15 but we do not expect the adoption thereof to have a material effect on the Company’s financial statements.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	12 Months Ended
Fair Value of Financial Instruments (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on a Recurring Basis	Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.


		As of December 31, 2014									As of December 31, 2013
	Assets and Liabilities	Quoted Prices			Significant		Significant		Balance as of		Quoted Prices		Significant		Significant		Balance at
		In Active			Other		Unobservable		December 31,		In Active		Other		Unobservable		December 31,
		Markets for			Observable		Inputs		2014		Markets for		Observable		Inputs		2013
		Identical			Inputs		(Level 3)				Identical		Inputs		(Level 3)
		Assets			(Level 2)						Assets		(Level 2)
		(Level 1)									(Level 1)
	Assets:
	Money market funds	$	49,856		$	—	$	—	$	49,856	$	30,325	$	—	$	—	$	30,325
	Total assets at fair value	$	49,856		$	—	$	—	$	49,856	$	30,325	$	—	$	—	$	30,325
	Liabilities:
	Warrant liability	$	—		$	—	$	8	$	8	$	—	$	—	$	19	$	19
	Total liabilities at fair value	$	—		$	—	$	8	$	8	$	—	$	—	$	19	$	19
Change in Fair Value Measurement Using Significant Unobservable Inputs (Level 3)	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below (in thousands):


	Balance at December 31, 2013	$	19
	Change in fair value recorded as interest income		(68	)
	Change in fair value recorded as interest expense		57
	Balance at December 31, 2014	$	8

Property_and_Equipment_net_Tab

Property and Equipment, net (Tables)	12 Months Ended
Property and Equipment, net (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands):


		As of December 31,
		2014			2013
	Leasehold improvements	$	—		$	333
	Computer equipment and software		223			184
	Laboratory equipment		—			1,775
	Furniture and equipment		186			27
	Less – Accumulated depreciation		(170	)		(2,211	)
	Property and equipment, net	$	239		$	108

Intangibles_Tables

Intangibles (Tables)	12 Months Ended
Intangibles (Tables)	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amounts and Accumulated Amortization of Intangible Assets Subject to Amortization	The following information details the carrying amounts and accumulated amortization of our intangible assets subject to amortization (in thousands):


		As of December 31, 2014								As of December 31, 2013
		Weighted		Gross		Accumulated		Net		Gross		Accumulated			Net
		Average		Carrying		Amortization		Carrying		Carrying		Amortization			Carrying
		Useful Life		Amount				Amount		Amount					Amount
		Remaining
	Identifiable intangible assets:
	Patents		8.0 years	$	—		—		—	$	1,518	$	(383	)	$	1,135
	Product licenses		2.0 years		—		—		—		1,555		(1,424	)		131
	Total		7.8 years	$	—		—		—	$	3,073	$	(1,807	)	$	1,266

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Aggregate Payments under Non-Cancelable Lease Obligations	Future minimum aggregate payments under non-cancelable lease obligations as of December 31, 2014 are as follows (in thousands):



	For the year ending December 31:	Amount
	2015	$	315
	2016		389
	2017		472
	2018		489
	2019		498
	thereafter		291

	Total minimum lease payments	$	2,454

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2014
Payables and Accruals [Abstract]
Components of Accrued Expenses	The components of accrued expenses are as follows (in thousands):



		As of December 31,
		2014		2013
	Accrued license milestones	$	—	$	1,000
	Accrued obligations under clinical contracts		—		1,957
	Accrued restructuring costs		4,591		—
	Accrued legal and professional services		276		152
	Accrued VAT expenses		780		780
	Accrued interest		21		24
	Accrued compensation and benefits		140		1,225
	Accrued expenses, other		490		386

	Total accrued expenses	$	6,298	$	5,524

Longterm_Debt_Tables

Long-term Debt (Tables)	12 Months Ended
Long-term Debt (Tables)	Dec. 31, 2014
Debt Disclosure [Abstract]
Summary of Comerica Debt	The Comerica debt is summarized as follows (in thousands):



			As of December 31,
			2014			2013
	Principal due in 2014		$	—		$	2,000
	Principal due in 2015			2,500			2,500
	Less: unamortized discount			(13	)		(103	)
	Plus – fees due at closing (1)			142			55

	Total Short Term Debt			2,629			4,452
	Less: current portion			(2,629	)		(2,000	)

	Long-term debt, net		$	—		$	2,452



	-1	On the date that all of the principal and interest of the Comerica Loan become due and payable, we must pay an end of term fee of $173,000 (the “Final Fee”). The Final Fee is being accreted to interest expense over the term of the Comerica Loan

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	12 Months Ended
Stock Based Compensation (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Weighted Average Assumptions Used to Value Stock Options on Date of Grant	The following table shows the weighted average assumptions used to value stock options on the date of grant, as follows:



			Year ended December 31,
			2014						2013
			Employee			Non-Employees			Employee			Non-Employees
	Expected stock price volatility			55.17	%		62.71	%		46	%		45.3	%

	Risk-free interest rate			1.33	%		0.1	%		1.04	%		0.37	%

	Expected life of option (in years)			3.2			0.6			3.69			2

	Estimated dividend yield			0	%		0	%		0	%		0	%

	Weighted-average grant date fair value per share		$	0.02		$	0.02			1.91			1.49
Summary of Aggregate Equity Compensation Plan Activity	The following table summarizes our aggregate Equity Compensation Plan activity:



			Number of			Weighted Average			Weighted Average			Aggregate
			Options			Exercise Price			Contractual			Intrinsic Value (1)
									Term
									(in years)
	Outstanding – January 1, 2014			3,272,847
	Granted			2,162,142
	Exercised			(12,161	)
	Forfeited			(1,428,678	)
	Expired			(155,028	)
	Outstanding – December 31, 2014			3,839,122		$	4.68			6.43		$	50,252

	Exercisable – December 31, 2014			2,067,500		$	5.43			4.99		$	14,657
	Vested and expected to vest at December 31,2014 (2)			3,825,209		$	4.67			6.42		$	49,761


	-1	Intrinsic value is the excess of the fair value of the underlying common shares as of December 31, 2014 over the weighted-average exercise price. A negative intrinsic value indicates the weighted-average exercise price is greater than the fair value of the underlying common shares as of December 31, 2014.
	-2	The number of stock options expected to vest takes into account an estimate of expected forfeitures.
Summary of Information about Options Outstanding	The following table summarizes certain information about all options outstanding as of December 31, 2014:



			Options Outstanding						Options Exercisable
	Exercise Price		Options			Weighted Average			Options			Weighted Average
			Outstanding			Remaining			Exercisable			Remaining
						Contractual Life						Contractual Life
						(Years)						(Years)

	$0.80 - $1.10			837,531			9.9			244,280			9.9

	$1.67 - $3.84			260,758			3.5			227,286			2.8

	$3.85 - $4.50			721,213			5.9			721,213			5.9

	$4.51 - $4.81			1,128,061			5.4			717,203			4

	$4.87 - $12.53			891,559			5.2			697,518			4.1

				3,839,122			6.4			2,607,500			5


	The following table summarizes certain information about all options outstanding as of December 31, 2013:



			Options Outstanding						Options Exercisable
	Exercise Price		Options			Weighted Average			Options			Weighted Average
			Outstanding			Remaining			Exercisable			Remaining
						Contractual Life						Contractual Life
						(Years)						(Years)

	$1.67-$3.84			334,921			5.8			254,829			5

	$4.00			1,366,760			9.6			4,256			1

	$4.51-$4.81			951,961			7.8			626,455			6.7

	$4.87-$12.53			619,205			5.2			501,113			4.1


				3,272,847			7.9			1,386,653			5.4

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Company's Deferred Income Tax Assets and Liabilities	Significant components of the Company’s deferred income tax assets and liabilities at December 31, 2014 and 2013, consisted of the following (in thousands):



		2014			2013
	Deferred income tax assets:
	Net operating loss carryforwards	$	78,276		$	53,436
	Property and equipment		8			136
	Stock-based compensation expense		1,403			661
	Accruals		1,700			1,220
	Other		20			44
	Valuation allowance for deferred income tax assets		(81,407	)		(54,999	)

	Net deferred income tax assets		—			498
	Deferred income tax liabilities:
	Patent costs		—			(498	)

	Net deferred income taxes	$	—		$	—

Schedule of Effective Income Tax Rate Reconciliation	The differences between the statutory rate and the effective rate are due to the valuation allowance and other permanent differences, as shown in the table below (dollars in thousands):




		2014						2013
		Tax			Rate			Tax			Rate
	Rate Reconciliation
	Tax at statutory rate	$	(23,489	)		35	%	$	(12,054	)		35	%
	Incentive stock options		19			(0.0	)%		148			(0.4	)%
	Non-deductibles		(19	)		0	%		—			0	%
	State taxes		(2,684	)		4	%		(1,378	)		4	%
	Contribution adjustment		19			(0.0	)%		—			0	%
	Federal NOL adjustment		(2,145	)		3.2	%		—			0	%
	State NOL adjustment		1,655			(2.5	)%		—			0	%
	Other deferred tax asset adjustment		235			(0.3	)%		—			0	%
	Change in valuation allowance		26,408			(39.4	)%		13,002			(37.8	)%
	Other		1			(0.0	)%		282			0.8	%

	Income tax expense reported	$	—			—	%	$	—			—	%

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
Net Loss Per Share (Tables)	Dec. 31, 2014
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Common Share	The following table presents the calculation of basic and diluted net loss per share of common stock attributable to the Company’s common stockholders (in thousands, except share and per share data):



		December 31,
		2014			2013
	Net loss per share:
	Numerator:
	Net loss	$	(67,112	)	$	(34,439	)
	Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock		(14,840	)		—

	Net loss attributable to stockholders		(81,952	)		(34,439	)
	Net loss attributable to preferred stockholders		(3,972	)		—

	Net loss attributable to common stockholders — basic and diluted		(77,980	)		(34,439	)

	Denominator:
	Weighted average common shares outstanding, basic and diluted		30,658,820			7,499,661

	Net loss per share attributable to common stockholders, basic and diluted	$	(2.54	)	$	(4.59	)

Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Securities that may potentially dilute earnings per share in the future that have not been included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):



		December 31,
		2014			2013
	Convertible preferred stock		2,000,000			—
	Common stock options		3,839,122			3,272,847
	Warrants		9,356			16,332

	Total		5,848,478			3,289,179

Organization_and_Description_o1

Organization and Description of Business - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended	1 Months Ended
	Aug. 25, 2014	Dec. 31, 2014	Sep. 30, 2013	Mar. 31, 2014	Apr. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
	Patient	Dec. 31, 2014	Sep. 30, 2013	Mar. 31, 2014	Apr. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Organization And Description Of Business [Line Items]
Number of patients enrolled	3,250
Number of subjects in Phase 3 trial	13,200
Common stock, shares issued		33,609,212				21,310,614
Proceeds from issuance of common stock		$34,000				$21,000
Net proceeds of common stock		18,600,000
Convertible preferred stock value		$1,000
Conversion of preferred stock into common stock		2,000,000
Cash flows from operating activities		-52,668,000
Cash and cash equivalents		51,557,000				30,688,000	14,764,000
Accumulated Deficit		-212,091,000				-144,979,000
Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Percentage of ownership in aggregate number of common stock		68.00%
Closing cash balance limit for adjusting exchange ratio		38,000,000
Number of board of directors seats		9,000,000
Potential reverse stock split ratio		Five to one reverse stock split
Potential reverse stock split ratio		200,000
Termination fee obligated to pay in addition to reimbursement fees		1,000,000
Additional termination fees		1,000,000
Merger Agreement [Member] \| Company Representatives [Member]
Organization And Description Of Business [Line Items]
Number of board of directors seats		3,000,000
Tobira Therapeutics Inc Member \| Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Number of board of directors seats		6,000,000
Common Class Undefined [Member]
Organization And Description Of Business [Line Items]
Number of common stock purchased by investors				2,000,000
Series F Convertible Preferred Stock [Member]
Organization And Description Of Business [Line Items]
Number of convertible preferred stock				10,000
Convertible preferred stock value				$1,000
Conversion of preferred stock into common stock				200
Maximum [Member] \| Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Reimburse fees and expenses		250,000
Termination fees in event of breach		250,000
Noncontrolling Interest [Member] \| Merger Agreement [Member]
Organization And Description Of Business [Line Items]
Percentage of ownership in aggregate number of common stock		32.00%
IPO [Member]
Organization And Description Of Business [Line Items]
Common stock, shares issued			11,671,500
Common stock price per share			$4
Proceeds from issuance of common stock			41,100,000
Underwriting discounts			3,300,000
Offering costs			2,300,000
Conversion of preferred stock into common stock			9,396,767
2014 Private Placement [Member]
Organization And Description Of Business [Line Items]
Common stock, shares issued		4,000,000		4,000,000
Common stock price per share		$5		$5
Net proceeds of common stock				20,000,000
April 2014 Offering [Member]
Organization And Description Of Business [Line Items]
Common stock price per share					$6
Proceeds from issuance of common stock					57,500,000
Underwriting discounts					3,700,000
Common stock public offering					10,000,000
Common stock price per share after deducting underwriting discounts and commissions					$5.64
Common stock, shares issued					279,461
Offering costs					$500,000

Basis_of_Presentation_and_Summ2

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Basis Of Presentation [Line Items]
Cash flows from operating activities	($52,668,000)
Highly liquid debt instruments, maturity period	3 months
Cash	1,700,000	363,000
Investments	49,900,000	30,300,000
Clinical trial supplies written down	8,200,000
Clinical trial supplies included in other current assets		4,600,000
In-process API held at the manufacturer		1,600,000
Drug product located at depots		3,000,000
Prepaid expenses related to clinical agreements	1,100,000
Upfront payments		4,500,000
VAT receivable, current	1,200,000	1,200,000
VAT liability	780,000	780,000
Impairment loss	2,057,000	371,000
Impairments of long-lived assets	8,190,000	0
Patents [Member]
Basis Of Presentation [Line Items]
Impairment loss	2,057,000	371,000
Patents [Member] \| Research and Development Expenses [Member]
Basis Of Presentation [Line Items]
Impairments of long-lived assets	371,000
Minimum [Member]
Basis Of Presentation [Line Items]
Property, plant and equipment useful lives	2 years
Maximum [Member]
Basis Of Presentation [Line Items]
Property, plant and equipment useful lives	5 years
Value Added Taxes [Member]
Basis Of Presentation [Line Items]
Impact of VAT on net loss	$0	$0

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Assets:
Money market funds	$49,856	$30,325
Liabilities:
Total liabilities at fair value	8	19
Warrant Liability [Member]
Liabilities:
Total liabilities at fair value	8	19
Money Market Funds [Member]
Assets:
Money market funds	49,856	30,325
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets:
Money market funds	49,856	30,325
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Money Market Funds [Member]
Assets:
Money market funds	49,856	30,325
Significant Unobservable Inputs (Level 3) [Member]
Liabilities:
Total liabilities at fair value	8	19
Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability [Member]
Liabilities:
Total liabilities at fair value	$8	$19

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Change in Fair Value Measurement Using Significant Unobservable Inputs (Level 3) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Balance at December 31, 2013	$19
Change in fair value recorded as interest income	-68
Change in fair value recorded as interest expense	57
Balance at December 31, 2014	$8

Property_and_Equipment_Net_Sch

Property and Equipment, Net - Schedule of Property and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Less - Accumulated depreciation	($170)	($2,211)
Property and equipment, net	239	108
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Computer equipment and software		333
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Computer equipment and software	223	184
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Computer equipment and software		1,775
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Computer equipment and software	$186	$27

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation expense	$127	$61

Intangibles_Summary_of_Carryin

Intangibles - Summary of Carrying Amounts and Accumulated Amortization of Intangible Assets Subject to Amortization (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life Remaining	7 years 9 months 18 days
Gross Carrying Amount		$3,073
Accumulated Amortization		-1,807
Net Carrying Amount		1,266
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life Remaining	8 years
Gross Carrying Amount		1,518
Accumulated Amortization		-383
Net Carrying Amount		1,135
Product Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life Remaining	2 years
Gross Carrying Amount		1,555
Accumulated Amortization		-1,424
Net Carrying Amount		$131

Intangibles_Additional_Informa

Intangibles - Additional Information (Detail) (USD $)	12 Months Ended
Intangibles - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Patent cost	$383,000	$557,000
Impairment loss	2,057,000	371,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment loss	2,057,000	371,000
Product Licenses Member
Finite-Lived Intangible Assets [Line Items]
Impairment loss	104,000	0
Product licensing cost	$7,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2007
	sqft	Dec. 31, 2014	Dec. 31, 2013	sqft
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Milestone payments		$0
Annual lease obligations in first year		315,000
Annual lease obligations in second year		389,000
Annual lease obligations in third year		472,000
Lease term, in months		36 months
Operating lease period	6 years
Area of administrative office	18,467
Contractual obligation	2,454,000	2,454,000
Rent expense, operating leases		478,000	464,000
Research and Development Expenses [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Milestone payments			1,000,000
MTS Partners L.P. [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Non-refundable fees		100,000
Transaction Fees		1,500,000
Stock issued for services		500,000
Non-refundable fees paid		100,000
Future payment of transaction		1,500,000
Duke University [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Milestone payments			500,000
Cowen and Company, LLC [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Stock issued for services		250,000
Future payment of transaction		0
Obligation fee due		500,000
Laboratory Space [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Operating lease				8,495
Operating lease expire date		31-Jul-12
Monthly operating lease payments		11,000
Operating lease period			1 year
Operating lease monthly base rent			13,000
Initial letter of credit to lessor		115,000
Reduced letter of credit on fourth anniversary date of lease		46,000
Accrued Expenses [Member] \| Archemix Corporation [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Milestone payments			1,000,000
Durham Office Lease [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Annual lease obligations in first year		39,000
Annual lease obligations in second year		40,000
Annual lease obligations in third year		$41,000

Commitments_Schedule_of_Future

Commitments - Schedule of Future Minimum Aggregate Payments under Non-Cancelable Lease Obligations (Detail) (USD $)	Dec. 31, 2014	Apr. 30, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014	Apr. 30, 2014
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$315
2016	389
2017	472
2018	489
2019	498
thereafter	291
Total minimum lease payments	$2,454	$2,454

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended
	Sep. 24, 2014	Sep. 26, 2013	Dec. 31, 2014	Dec. 31, 2013	Sep. 24, 2014
	Method	Method	Dec. 31, 2014	Dec. 31, 2013	Sep. 24, 2014
Restructuring Cost and Reserve [Line Items]
Number of full-time employees	32
Number of eliminated employees	28	5
Percentage of reduction in company's workforce eliminated	88.00%
Accrued severance cost	$4,600,000		$4,591,000		$4,600,000
Number of eliminated employees		32
Severance expense			3,300,000	667,000
Accrued severance expense			2,600,000	417,000
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Accrued severance cost	$7,000,000				$7,000,000

Accrued_Expenses_Components_of

Accrued Expenses - Components of Accrued Expenses (Detail) (USD $)	Dec. 31, 2014	Sep. 24, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 24, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued license milestones			$1,000
Accrued obligations under clinical contracts			1,957
Accrued restructuring costs	4,591	4,600
Accrued legal and professional services	276		152
Accrued VAT expenses	780		780
Accrued interest	21		24
Accrued compensation and benefits	140		1,225
Accrued expenses, other	490		386
Total accrued expenses	$6,298		$5,524

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended		1 Months Ended
Long-term Debt - Additional Information (Detail) (USD $)	13-May-13	Dec. 31, 2014	Dec. 31, 2013	31-May-11
Debt Instrument [Line Items]
Short term debt		$2,629,000	$4,452,000
Series E Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Issuance of warrants to purchase of stock		12.02	6.96
Comerica Bank [Member]
Debt Instrument [Line Items]
Loan and security agreement, borrowed amount	4,500,000
Loan and security agreement, interest rate spread		4.00%
Loan and security agreement, repayment description		The terms allow for an interest only period of 15 months, and the remaining principal and interest will be repaid starting September 2014 over a nine-month period (24 months in total), maturing in 2015.
Venture debt loan, LIBOR period		30 days
Venture debt loan, basis points		2.50%
Debt instrument term	24 months
Venture debt loan, interest period	15 months
Venture debt loan, interest rate		7.25%
Due period for repayment of principal and interest	9 months
Loan maturity year		2015
Venture debt loan, Description		Upon (i) Comericabs receipt of evidence satisfactory to Comerica that the 1,000 patient interim analysis in the REGULATE-PCI study is successful and performed by April 30, 2014 and (ii) our completion of the IPO and receipt of net proceeds of at least $50.0 million prior to June 30, 2013, we had the option to borrow an additional $4.0 million in the second tranche, or (bTranche Twob). Since the latter of the Tranche Two conditions was not satisfied, Tranche Two is solely at the discretion of Comerica.
Debt security, option to borrow additional loans		4,000,000
Short term debt		2,629,000	4,452,000
Comerica Bank [Member]
Debt Instrument [Line Items]
Loan and security agreement, interest expense		575,000	355,000
Comerica Bank [Member] \| Series E Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Issuance of warrants to purchase of stock		156,250
Warrant price per share		$0.72
Comerica Bank [Member] \| Common Class Undefined [Member]
Debt Instrument [Line Items]
Issuance of warrants to purchase of stock		9,356
Warrant price per share		$12.02
MidCap Financial SBIC, LP [Member]
Debt Instrument [Line Items]
Loan and security agreement, borrowed amount				6,000,000
Loan and security agreement, floor interest rate				2.00%
Loan and security agreement, interest rate spread				8.00%
Loan and security agreement, variable interest rate basis		LIBOR
Loan and security agreement, interest rate description		The stated rate of LIBOR, at a 2% rate floor, plus 8% spread per annum.
Final payment of loan and security agreement, percentage				3.00%
Final payment of loan and security agreement				180,000
Loan and security agreement, repayment description		The loan was payable in monthly installments beginning May 2012 through August 2014.
Loan and security agreement, repayment start date				2013-05
Loan and security agreement, repayment end date				2013-08
MidCap Loan [Member]
Debt Instrument [Line Items]
Loan and security agreement, interest expense		$0	$325,000

Longterm_Debt_Summary_of_Comer

Long-term Debt - Summary of Comerica Debt (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Principal due in 2014		$2,000
Principal due in 2015	2,500	2,500
Less: unamortized discount	-13	-103
Plus - fees due at closing	142	55
Total Short Term Debt	2,629	4,452
Total Short Term Debt	2,629	4,452
Less: current portion	-2,629	-2,000
Long-term debt, net		$2,452

Longterm_Debt_Summary_of_Comer1

Long-term Debt - Summary of Comerica Debt (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt instrument end of term fee	$173,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 18, 2012	Dec. 31, 2013	Apr. 30, 2014	Mar. 31, 2014	Mar. 21, 2014
Subsidiary, Sale of Stock [Line Items]
Authorized shares	501,000,000
Common stock, shares authorized	500,000,000		500,000,000
Common stock, par value	$0.00		$0.00
Proceeds from issuance of common stock	$34,000		$21,000
Sale of additional preferred stock, shares	0
Number of common stock sold	33,609,212		21,310,614
Proceeds from private placement	18,600,000
Equity exchange par or stated value	$1,000
Conversion of preferred stock into common stock	2,000,000
Conversion price of common stock	$5
Beneficial ownership for conversion of preferred stock into common stock	9.99%
Beneficial conversion feature amount	14,800,000
Series E Convertible Preferred Stock [Member] \| Second Tranche [Member]
Subsidiary, Sale of Stock [Line Items]
Number of preferred shares issued		14,320,168
Carrying value of preferred stock		10,300,000
Preferred stock, financing tranche effective date		22-Mar-13
Series E Convertible Preferred Stock [Member] \| Third Tranche [Member]
Subsidiary, Sale of Stock [Line Items]
Number of preferred shares issued	24,770,476
Carrying value of preferred stock	17,800,000
Series E Convertible Preferred Stock [Member] \| Third Tranche [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, financing tranche effective date	17-Jan-14
Series F Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	1,000,000		1,000,000
Preferred stock, par value	$1,000		$1,000
Number of preferred shares issued	10,000		0
Carrying value of preferred stock	24,832,000
Equity exchange stock received						10,000
Equity exchange par or stated value						$1,000
Conversion of preferred stock into common stock						200
Discount related to beneficial conversion feature	14,800,000
Increase in carrying value of preferred stock	14,800,000
Series E Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding	$9,356		$16,332
Issuance of warrant to purchase of common stock	12.02		6.96
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrant to purchase of common stock	6,976
Warrant exercised for common stock at an exercise price	$0.17
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized	500,000,000
Common stock, par value	$0.00
Common stock, shares issued	10,279,000		11,672,000
Equity exchange stock issued						2,000,000
Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	1,000,000
Preferred stock, par value	$0.00
April 2014 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock public offering				10,000,000
Common stock, shares issued				279,461
Common stock price per share				$6
Common stock price per share after deducting underwriting discounts and commissions				$5.64
Proceeds from issuance of common stock				57,500,000
Underwriting discounts				3,700,000
Offering costs				500,000
Lock in period for transfer of common stock	90 days
Pre IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Authorized shares	698,363,299
Pre IPO [Member] \| Pre-IPO Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized	500,000,000
Common stock, par value	$0.00
Pre IPO [Member] \| Pre-IPO Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	198,363,299
Preferred stock, par value	$0.00
Pre IPO [Member] \| Series A Convertible Preferred Stock [Member] \| Pre-IPO Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	5,798,178
Pre IPO [Member] \| Series B Convertible Preferred Stock [Member] \| Pre-IPO Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	16,666,665
Pre IPO [Member] \| Series C Convertible Preferred Stock [Member] \| Pre-IPO Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	17,037,037
Pre IPO [Member] \| Series D Convertible Preferred Stock [Member] \| Pre-IPO Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	71,666,667
Pre IPO [Member] \| Series E Convertible Preferred Stock [Member] \| Pre-IPO Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized	87,194,752
Post IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred stock into common stock	9,396,767
2014 Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock price per share	$5				$5
Number of common stock sold	4,000,000				4,000,000
Proceeds from private placement					20,000,000
Offering costs					$1,400,000

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining stock options outstanding to acquire common stock, assumed under the 2013 plan	3,839,122	3,272,847
Expected dividend rate	0.00%
Intrinsic value of options exercised	$30,000	$11,000
Stock-based compensation	1,952,000	988,000
Expenses related to options issued to non-employees	0	59,000
Total unrecognized compensation related to unvested	$1,030,000
Recognized over a weighted-average period	2 years 3 months 18 days
Experience Group One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeiture rate	0.00%
Experience Group Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeiture rate	1.00%
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares authorized for future issuance	4,408,369	3,342,839
Common shares available for grant	289,741
Remaining stock options outstanding to acquire common stock, assumed under the 2013 plan	1,406,910
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for grant	0
Stock option to acquire common stock	34,342
Evergreen Provision [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for grant	1,680,461	1,065,530
Percentage of Common Stock outstanding		5.00%

Stock_Based_Compensation_Summa

Stock Based Compensation - Summary of Weighted Average Assumptions Used to Value Stock Options on Date of Grant (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	55.17%	46.00%
Risk-free interest rate	1.33%	1.04%
Expected life of option (in years)	3 years 2 months 12 days	3 years 8 months 9 days
Estimated dividend yield	0.00%	0.00%
Weighted-average grant date fair value per share	$0.02	$1.91
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	62.71%	45.30%
Risk-free interest rate	0.10%	0.37%
Expected life of option (in years)	7 months 6 days	2 years
Estimated dividend yield	0.00%	0.00%
Weighted-average grant date fair value per share	$0.02	$1.49

Stock_Based_Compensation_Summa1

Stock Based Compensation - Summary of Aggregate Equity Compensation Plan Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options, Outstanding, Beginning Balance	3,272,847
Number of Options, Granted	2,162,142
Number of Options, Exercised	-12,161
Number of Options, Forfeited	-1,428,678
Number of Options, Expired	-155,028
Number of Options, Outstanding, Ending Balance	3,839,122
Number of Options, Exercisable	2,067,500
Number of Options, Vested and expected to vest	3,825,209
Weighted Average Exercise Price, Outstanding	$4.68
Weighted Average Exercise Price, Exercisable	$5.43
Weighted Average Exercise Price, Outstanding, Vested and expected to vest	$4.67
Weighted Average Contractual Term, Outstanding	6 years 5 months 1 day
Weighted Average Contractual Term, Exercisable	4 years 11 months 27 days
Weighted Average Contractual Term, Vested and Expected to Vest	6 years 5 months 5 days
Aggregate Intrinsic Value of Stock Options Outstanding	$50,252
Aggregate Intrinsic Value of Stock Options Exercisable	14,657
Aggregate Intrinsic Value of Stock Options Vested and Expected to Vest	$49,761

Stock_Based_Compensation_Summa2

Stock Based Compensation - Summary of Information about Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding	3,839,122	3,272,847
Weighted Average Remaining Contractual Life(Years), Outstanding	6 years 4 months 24 days	7 years 10 months 24 days
Options Exercisable	2,607,500	1,386,653
Weighted Average Remaining Contractual Life(Years), Exercisable	5 years	5 years 4 months 24 days
Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding	837,531	334,921
Weighted Average Remaining Contractual Life(Years), Outstanding	9 years 10 months 24 days	5 years 9 months 18 days
Options Exercisable	244,280	254,829
Weighted Average Remaining Contractual Life(Years), Exercisable	9 years 10 months 24 days	5 years
Exercise Price Range One [Member] \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	0.8	1.67
Exercise Price Range One [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	1.1	3.84
Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price		4
Options Outstanding	260,758	1,366,760
Weighted Average Remaining Contractual Life(Years), Outstanding	3 years 6 months	9 years 7 months 6 days
Options Exercisable	227,286	4,256
Weighted Average Remaining Contractual Life(Years), Exercisable	2 years 9 months 18 days	1 year
Exercise Price Range Two [Member] \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	1.67
Exercise Price Range Two [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	3.84
Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding	721,213	951,961
Weighted Average Remaining Contractual Life(Years), Outstanding	5 years 10 months 24 days	7 years 9 months 18 days
Options Exercisable	721,213	626,455
Weighted Average Remaining Contractual Life(Years), Exercisable	5 years 10 months 24 days	6 years 1 month 6 days
Exercise Price Range Three [Member] \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	3.85	4.51
Exercise Price Range Three [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	4.5	4.81
Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding	1,128,061	619,205
Weighted Average Remaining Contractual Life(Years), Outstanding	5 years 4 months 24 days	5 years 2 months 12 days
Options Exercisable	717,203	501,113
Weighted Average Remaining Contractual Life(Years), Exercisable	4 years	4 years 1 month 6 days
Exercise Price Range Four [Member] \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	4.51	4.87
Exercise Price Range Four [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	4.81	12.53
Exercise Price Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding	891,559
Weighted Average Remaining Contractual Life(Years), Outstanding	5 years 2 months 12 days
Options Exercisable	697,518
Weighted Average Remaining Contractual Life(Years), Exercisable	4 years 1 month 6 days
Exercise Price Range Five [Member] \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	4.87
Exercise Price Range Five [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	12.53

Employee_Benefit_Plan_Addition

Employee Benefit Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Bonus [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Shares outstanding	0	0
401k Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Eligible percentage that employees can defer from their compensation	87.00%
Matching contributions made by company for elective deferrals	50.00%
Aggregate matching contribution expense	$101,000	$88,000
Employee Stock Purchase Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Shares outstanding	0	0
Common stock may be issued pursuant to the ESPP	96,360

Income_Taxes_Components_of_Com

Income Taxes - Components of Company's Deferred Income Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred income tax assets:
Net operating loss carryforwards	$78,276	$53,436
Property and equipment	8	136
Stock-based compensation expense	1,403	661
Accruals	1,700	1,220
Other	20	44
Valuation allowance for deferred income tax assets	-81,407	-54,999
Net deferred income tax assets		498
Deferred income tax liabilities:
Patent costs		-498
Net deferred income taxes	$0	$0

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Rate Reconciliation
Tax at statutory rate	($22,789)	($12,054)
Incentive stock options	492	148
Non-deductibles	-19
State taxes	-2,604	-1,378
Contribution adjustment	19
Federal NOL adjustment	-2,145
State NOL adjustment	1,655
Other deferred tax asset adjustment	235
Change in valuation allowance	25,154	13,002
Other	-253	282
Income tax expense reported	$0	$0
Rate Reconciliation
Tax at statutory rate	35.00%	35.00%
Incentive stock options	0.00%	-0.40%
Non-deductibles	0.00%	0.00%
State taxes	4.00%	4.00%
Contribution adjustment	0.00%	0.00%
Federal NOL adjustment	3.20%	0.00%
State NOL adjustment	-2.50%	0.00%
Other deferred tax asset adjustment	-0.30%	0.00%
Change in valuation allowance	-39.40%	-37.80%
Other	0.00%	0.80%
Income tax expense reported	0.00%	0.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Operating loss carry forwards	$205,600,000	$257,900,000
Change in ownership percentage points	5000.00%
Liability for uncertain tax positions	0	0
Accrued interest or penalties associated with any unrecognized tax positions	$0
Maximum [Member]
Income Taxes [Line Items]
Percentage likely of largest amount of tax benefit being realized upon ultimate settlement with tax authority	5000.00%
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating loss carry forwards expiration year	2022
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss carry forwards expiration year	2017

Net_Loss_per_Share_Additional_

Net Loss per Share - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014
Earnings Per Share [Abstract]
Deemed dividend related to beneficial conversion feature of Series F convertible preferred stock	$14,800	$14,840

Net_Loss_per_Share_Calculation

Net Loss per Share - Calculation of Basic and Diluted Net Loss Per Share of Common Stock Attributable to Company's Common Stockholders (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss		($67,112)	($34,439)
Deemed dividend related to the beneficial conversion feature of Series F convertible preferred stock	-14,800	-14,840
Net loss attributable to stockholders		-81,952	-34,439
Net loss attributable to preferred stockholders		-3,972
Net loss attributable to common stockholders - basic and diluted		($77,980)	($34,439)
Denominator:
Weighted average common shares outstanding, basic and diluted		30,658,820	7,499,661
Net loss per share attributable to common stockholders, basic and diluted		($2.54)	($4.59)

Net_Loss_per_Share_Schedule_of

Net Loss per Share - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,848,478	3,289,179
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,000,000
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,839,122	3,272,847
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,356	16,332